Archives: Premium Distribution

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”), Parkinson’s disease and multiple sclerosis (“MS”), along with subsidiary Clene Nanomedicine, is announcing the publication of a peer-reviewed article describing brain target engagement by CNM-Au8(R), the company’s lead drug candidate. Coauthored by physician scientists from the University of Texas Southwestern Medical Center and Clene, the paper is titled “Evidence of Brain Target Engagement in Parkinson’s Disease and Multiple Sclerosis by the Investigational Nanomedicine, CNM-Au8, in the REPAIR Phase 2 Clinical Trials” and was published in the “Journal of Nanobiotechnology.” The article outlines results from the successful phase 2 REPAIR clinical studies designed to evaluate and measure changes in brain-energy metabolites in multiple sclerosis and Parkinson’s disease when treated with CNM-Au8. The data indicated a significant increase in brain NAD+/NADH ratio from baseline, the studies’ primary endpoint, following 12 weeks of daily oral dosing of CNM-Au8 with the study concluding that CNM-Au8 treatment resulted in favorable modulation of additional brain energy metabolites that have been shown to be dysregulated in neurodegenerative diseases. “We believe the 10.4% increase in brain NAD+/NADH ratio to be clinically significant,” said Clene head of medical Dr. Benjamin Greenberg in the press release. “Other groups have shown significant deficits in brain-energy metabolites associated with neurodegenerative disease. For example, brain levels of NAD are deficient in Parkinson’s disease, and deficits in brain ATP levels correlate with the Expanded Disability Status clinical scale for multiple sclerosis. Even in healthy aging, the human brain’s NAD+/NADH decreases at a rate of loss of approximately half a percent per decade. Elevation of brain NAD+/NADH levels to many times the rate of loss observed in healthy aging is a significant and very promising effect.”

To view the full article, visit https://ibn.fm/gwQA8

To view the full press release, visit https://ibn.fm/SA476

About Clene Inc.

Clene and its wholly owned subsidiary, Clene Nanomedicine, is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8(R) is an investigational, first-in-class therapy that improves the survival and function of central nervous system cells via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8 is a federally registered trademark of Clene Nanomedicine. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

Freight Technologies (NASDAQ: FRGT), a technology-driven logistics company powered by its proprietary artificial intelligence (“AI”) and machine learning Fr8App platform has been selected by Amazon Mexico (Amazon.com Inc. (NASDAQ: AMZN)) again for its logistical solutions. Fr8App uniquely provides a real-time portal for business-to-business (“B2B”) cross-border shipping and domestic shipping within the United States, Mexico, and Canada (“USMCA”) region. According to the announcement, Amazon Mexico has chosen Fr8App for the second year in a row to support and assist with navigating the logistic complexities of the high-demand season. The company reported that more than 670 cargo loads have been moved between Amazon distribution centers using Fr8App, solidifying the platform’s pivotal role in providing a seamless “flow of goods” across the country for Amazon. “Our commitment to meeting customer’s needs and our continuous platform improvements have led to this exciting opportunity,” said Freight Technologies CEO Javier Selgas in the press release. “Amazon’s decision to choose Fr8App during their high-demand season validates our capabilities and positions us as the go-to logistics solution for B2B, cross-border and domestic shipping within the USMCA region. We’re excited to work for a prominent market leader like Amazon, and we’re confident in our ability to meet their stringent standards throughout the year as they continue to expand.”

To view the full press release, visit https://ibn.fm/v1sFX

About Freight Technologies Inc. 

Freight Technologies is a technology company developing solutions to optimize and automate the supply chain process. Its wholly owned subsidiary, Freight App Inc. (“Fr8App”), is a business-to-business, cross-border shipping marketplace in the USMC region powered by artificial intelligence (“AI”) and machine learning. Focused on making shipping transparent and efficient, Fr8App provides carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road (“OTR”) shipping. Fr8App uses its proprietary technology platform to connect carriers and shippers and significantly improve matching and operation efficiency via innovative technologies such as live pricing and real-time tracking, digital freight marketplace, broker, transportation management, fleet management and committed capacity solutions. The company is headquartered in Houston, Texas. For more information about the company, please visit www.FR8Technologies.com.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

• Lexaria, a global innovator in drug delivery platforms, is projected by Zacks SCR to be valued at $10 a share, up from the current $1.50 for 2024
• Zacks SCR projects a 259% YOY revenue growth for 2024 and a 20% growth for 2025, dependent upon the ultimate approval and commercialization of products employing its patented DehydraTECH(TM) technology
• Lexaria also anticipates FDA approval for its IND application and commence its Phase 1b hypertension clinical trial, all in 2024

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has had significant developments in 2023. Most notably, the company has seen more positive results for its patented DehydraTECH(TM) technology for various indications, including potential diabetes treatment, oral nicotine, and hypertension. Results in these studies set the stage for additional clinical trials for 2024. These have contributed to the company’s projected valuation of $10 a share, up from the current $1.50, per a recent Zacks SCR report (https://cnw.fm/ifIlY).

Zacks SCR projects 259% year-over-year (“YOY”) revenue growth for 2024 and a 20% YOY growth for 2025. This progression will largely depend on the ultimate approval and commercialization of products employing its DehydraTECH technology, mainly since the company receives most of its revenues from…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (“CBDW”) is a specialized communications platform with a focus on CBD related news and updates in the cannabidiol (“CBD”) sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled recognition and brand awareness.

CBDW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CBDWire, text “CBDWire” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://www.CBDWire.com/Disclaimer

CBDWire
Denver, CO
www.CBDWire.com
303.498.7722 Office
[email protected]

CBDWire is powered by IBN

Vision Marine Technologies (NASDAQ: VMAR), a global leader and innovator within the performance electric recreational boating industry, was featured in the most recent offering from the Bell2Bell Podcast. During the interview, host Stuart Smith and Vision Marine Technologies head of investor relations Bruce Nurse talked about the company and its innovation within the performance electric recreational boating industry. During the interview, Nurse provided an overview of Vision Marine Technologies and its business model, noting that the company’s focus is to disrupt the traditional boating industry by transforming the boating experience with electric power. Nurse explained that this type of transformation is already happening in the auto industry, with auto manufacturers now offering options for consumer to drive electric, but those same options aren’t seen on the water. Nurse noted the pollution that has resulted and explained that the company has invested significant amounts of funds and time into R&D with the objective of bringing fully electric solutions to the waterways. The Bell2Bell Podcast is part of the sustained efforts of IBN, a multifaceted communications organization, to connect public companies with the investment community. The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. “In August, for the Lake of the Ozarks Shootout, we built a carbon fiber boat with two of our E-Motion(TM) powertrains,” said Vision Marine Technologies head of investor relations Bruce Nurse during the interview. “It was piloted by Shaun Torrente, a world champion boat racer who races for the Abu Dhabi race team. . . . We hit 116 miles an hour, beating the previous record, which happened to be held by Vision Marine at 109 miles an hour. . . .It’s how you harness energy from the battery to the motor to the propeller, and that’s our expertise. That’s our patented IP and technology that we bring.”

To listen to the full interview, visit https://ibn.fm/OG32W

To view the full press release, visit https://ibn.fm/JnlQf

About Vision Marine Technologies Inc.

Vision Marine Technologies strives to be a guiding force for change and an ongoing driving factor in fighting the problems associated with waterway pollution by disrupting the traditional boating industry with electric power, in turn directly contributing to zero pollution, zero emission and a noiseless environment. The company’s Flagship E-Motion(TM) 180E electric marine powertrain is the first fully electric, purpose-built outboard powertrain system that combines an advanced battery pack, inverter and high-efficiency motor with proprietary union assembly between the transmission and the electric motor design utilizing extensive control software. VMAR’s E-Motion and related technologies used in this powertrain system are uniquely designed to improve the efficiency of the outboard powertrain and, as a result, enhance both range and performance. Vision Marine continues to design, innovate, manufacture and sell handcrafted, environmentally friendly, electric recreational boats to customers. The design and technology applied to its boats result in far greater enhanced performance in general, higher speeds, longer range and a smoother ride than a traditional internal combustion engine (“ICE”) motorboat. For more information about the company, please visit www.VisionMarineTechnologies.com.

NOTE TO INVESTORS: The latest news and updates relating to VMAR are available in the company’s newsroom at http://ibn.fm/VMAR

About TechMediaWire

TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer

TechMediaWire
Los Angeles, CA
www.TechMediaWire.com
310.299.1717 Office
[email protected]

TechMediaWire is powered by IBN

Astrotech (NASDAQ: ASTC), an innovative science and technology company, has formed a new wholly owned subsidiary: Pro-Control Inc. According to the announcement, Pro-Control is unveiling its proprietary Pro-Control Maximum Value Process(TM) (Pro-Control MVP(TM) and the Pro-Control-1000(TM) mass spectrometer. The spectrometer has been designed to work within a chemical factory analyzing real-time samples while achieving optimized yields, quality and profits. It tests, measures and increases potency, purity and weight yields. Astrotech has entered into an exclusive license with Pro-Control to use the ATi mass spectrometer technology for chemical manufacturing process control applications. The Pro-Control MVP rapid test can take up to 20 tests per hour, greatly increase efficiency. The test has potential in numerous chemical manufacturing markets, including solvents and diluents, preservatives, flavoring agents, emulsifiers, food products, lubricants, oils and essential oils, terpenes, aromatic compounds, epoxy resins, modifiers, additives, pharmaceuticals, nutraceuticals and more. “We are very excited to be introducing the Pro-Control Maximum Value Processing(TM) method that has been diligently designed to improve many types of chemical distillation,” said Astrotech CEO and CTO Tom Pickens in the press release. “Our ideal customer is the high-volume distiller that can implement Pro-Control MVP(TM) and start realizing increased profits. We believe that the Pro-Control MVP has the ability to routinely improve yields by over 30% and are looking forward to introducing Pro-Control to the very large and valuable worldwide chemical manufacturing and tolling markets.”

To view the full press release, visit https://ibn.fm/lUUrv

About Astrotech Corp.

Astrotech is an innovative science and technology company that invents, acquires and commercializes technological innovations while building scalable companies to maximizing shareholder value. For more information, please visit www.AstrotechCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to ASTC are available in the company’s newsroom at https://ibn.fm/ASTC

About TechMediaWire

TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer

TechMediaWire
Los Angeles, CA
www.TechMediaWire.com
310.299.1717 Office
[email protected]

TechMediaWire is powered by IBN

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products, has announced successful preclinical trial results of its innovative anti–IL–17 VHH antibody (“NanoAb”). The trial evaluated Scinai’s NanoAbs as a local treatment for the large and underserved population of mild to moderate plaque psoriasis. The study was conducted by Genoskin, a French biotechnology company. According to the announcement, Genoskin’s human skin models were induced for expression of plaque psoriasis symptoms, thereby enabling ex–vivo examination of the therapeutic effects of drugs targeting underlying mechanisms in the pathogenesis of plaque psoriasis, specifically the IL-17 family of pro-inflammatory cytokines. The results exhibited the potential for Scinai’s anti-IL-17 NanoAbs to improve psoriatic skin lesions. The company noted that the results confirm and build upon previous studies and reports. “These positive results mark a significant step forward in the development of a novel treatment for the undertreated segment of mild and moderate plaque psoriatic patients,” said Scinai Immunotherapeutics chief scientist Dr. Tamar Ben-Yedidia in the press release. “To date, most of the innovation related to treatment of autoimmune diseases focused on drugs aimed at the more severe cases of these diseases, leaving milder cases with generic topical drugs and phototherapy treatments. The mild psoriatic patients account for more than 50% of the plaque psoriatic patients, and while undertreated they are prone to disease deterioration and worsening of symptoms, mainly painful skin lesions. Scinai’s vision is to become the ‘Botox-like solution,’ providing a highly efficacious, specific and safe biologic for local treatment of plaque psoriasis lesions.”

To view the full press release, visit https://ibn.fm/iwUQU

About Scinai Immunotherapeutics Ltd. 

Scinai Immunotherapeutics is a biopharmaceutical company with two complementary business units: one focused on in-house development of inflammation and immunology (“I&I”) biological products beginning with an innovative, derisked pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO (“CDMO”) providing services to help biotech companies efficiently bring their products to market by leveraging Scinai’s drug development and GMP and non-GMP manufacturing capabilities for preclinical and clinical studies. For more information, visit the company’s website at www.Scinai.com.

NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

• SuperCom, a leading provider of traditional and digital identity solutions, is offering advanced electronic monitoring solutions to address the growing cases of domestic violence worldwide
• Considering just the United States, domestic violence is now believed to affect 3 out of 10 women and 1 in 10 men
• With its PureProtect electronic monitoring technology, SuperCom is offering law enforcement near real-time information and many lines of communication, allowing for superior victim protection with the enforcement of court restrictions

SuperCom (NASDAQ: SPCB), a global leading provider of traditional and digital identity solutions, offering advanced safety, identification, and security products and solutions to governments, is using advanced technology to reduce and prevent crime, specifically domestic violence. Through its propriety electronic monitoring (“EM”) platform, the company offers advanced EM solutions and services that have repeatedly been shown to protect domestic violence victims in multiple countries.

This comes in the wake of growing cases of domestic violence, a situation which is now encouraging governments to explore monitoring technology as a way to mitigate these cases. In England and Wales alone, a crime survey revealed that an estimated 2.1 million people aged 16 years and over experienced…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

About TechMediaWire

TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer

TechMediaWire
Los Angeles, CA
www.TechMediaWire.com
310.299.1717 Office
[email protected]

TechMediaWire is powered by IBN

Turbo Energy (NASDAQ: TURB), a Valencia-based company specializing in photovoltaic energy storage solutions, today announced that Movistar has launched Turbo Energy’s GoSolar offering for sale this week through Movistar’s energy branch, Solar360. A telecommunications leader in Spain and Latin America, Movistar has been recognized as one of the world’s top 500 most valuable companies in the 2023 Global 500 rankings by Brand Finance. This highlights Movistar’s commitment to sustainability and innovation, aligning with Turbo Energy’s pursuit of cleaner and more efficient solutions in the field of photovoltaic generation. “It is very gratifying for us to see that Movistar, a leading home-services brand, is committed to Turbo Energy,” said TURB General Manager Mariano Soria. “It encourages us to continue researching and developing products that contribute to the sustainable reduction of energy costs for thousands of homes and businesses.”

To view the full press release, visit https://ibn.fm/ikauI

About Turbo Energy S.A.

Turbo Energy is a leading photovoltaic energy storage technology company based in Valencia, Spain. The company develops innovative solutions that allow end consumers to harness the full potential of solar energy and reduce their electricity costs. With a combination of artificial intelligence and advanced technology, Turbo Energy is paving the way toward a more sustainable and energy-efficient future. For more information, visit the company’s website at www.Turbo-E.com.

NOTE TO INVESTORS: The latest news and updates relating to TURB are available in the company’s newsroom at https://ibn.fm/TURB

About GreenEnergyStocks

GreenEnergyStocks (“GES”) is a specialized communications platform with a focus on companies working to shape the future of the green economy. GreenEnergyStocks is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, GES is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, GES brings its clients unparalleled recognition and brand awareness. GES is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from GreenEnergyStocks, text “Green” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenEnergyStocks.com

Please see full terms of use and disclaimers on the GreenEnergyStocks website applicable to all content provided by GES, wherever published or re-published: https://www.greennrgstocks.com/Disclaimer

GreenEnergyStocks
Los Angeles, CA
www.GreenEnergyStocks.com
310.299.1717 Office
[email protected]

GreenEnergyStocks is powered by IBN

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products, is announcing the publication of a peer-reviewed article regarding NanoAbs. The article reports on data that supports the use of Scinai’s aerosolized NanoAbs as a platform for the treatment of hyperinflammatory viral diseases, which addresses significant medical needs. Titled “Nanobodies to multiple spike variants and inhalation of nanobody-containing aerosols neutralize SARS-CoV-2 in cell culture and hamsters,” the article is published in the prominent “Antiviral Research” journal. According to the announcement, the article focused on a new generation of anti-SARS-CoV-2 NanoAbs, identified as nanobodies or VHH (“VHH”) antibodies. These antibodies were developed as the result of a research collaboration between the Max Planck Institute for Multidisciplinary Sciences (“MPI-NAT”), the University Medical Center Göttingen (“UMG”) and Scinai Immunotherapeutics. The antibodies, which are alpaca–derived recombinant variable domain of heavy-chain-only antibodies, are exclusively licensed to Scinai. Scinai chief scientist Dr. Tamar Ben-Yididia coauthored the paper with Professor Dirk Görlich, MPI-NAT director, and UMG Professor Matthias Dobbelstein, along with others.

“These results are a striking proof-of-concept for the use of inhaled NanoAbs for the treatment of hyperinflammatory respiratory viral diseases,” said Scinai chief scientist Dr. Tamar Ben-Yididia in the press release. “We are proud that our first NanoAb development project has been published in the prestigious peer-reviewed scientific journal ‘Antiviral Research,’ as it validates our R&D strategy by clearly demonstrating our NanoAbs’ potential superiority to existing therapies in several ways, including innate stability leading to more convenient routes of administration such as inhalation. While COVID-19 has dropped from the headlines, it continues to circulate and cause illness. We strongly believe that convenient self-administered treatments and prophylactics form the future of respiratory viral-disease pharmaceuticals, and the data in this paper demonstrates the exciting potential of our NanoAbs to fill this vital role. Indeed, we are currently actively marketing this COVID-19 project for partnering with either pharma companies or governmental health agencies. Our next pipeline project is an anti-IL-17 NanoAb for the treatment of autoimmune diseases such as plaque psoriasis and psoriasis arthritis. Recent preclinical results have been promising, and I look forward to sharing more results soon.”

To view the article, visit https://ibn.fm/fKgtl

To view the full press release, visit https://ibn.fm/0EqAf

About Scinai Immunotherapeutics Ltd. 

Scinai Immunotherapeutics is a biopharmaceutical company with two complementary business units: one focused on in-house development of inflammation and immunology (“I&I”) biological products beginning with an innovative, derisked pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO (“CDMO”) providing services to help biotech companies efficiently bring their products to market by leveraging Scinai’s drug development and GMP and non-GMP manufacturing capabilities for preclinical and clinical studies. For more information, visit the company’s website at www.Scinai.com.

NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

• As a European innovator with a worldwide outlook, Turbo Energy designs devices that showcase how AI can be applied to enhance everyday living with advanced software systems that monitor the generation, use, and management of photovoltaic energy
• Turbo Energy’s SunBox, or what the company calls one of the most advanced systems on the market, does not just aim to save power; it seeks to empower users with smart tools that help them make energy choices that suit their lifestyle
• Expanding beyond residential applications, Turbo Energy introduced commercial and industrial-scale solutions in 2023 and aims for a global footprint in fourteen countries

A decade ago, Turbo Energy (NASDAQ: TURB) surfaced as a company focused on disruptive photovoltaic energy technology. Its ambitious goal was to transform storage technology for off-grid residences. Now, integrated into a group boasting more than 20 years of industry experience, the company is unwaveringly committed to developing innovative photovoltaic management solutions tailored for residential, commercial, and industrial markets.

A device capable of connecting to everything—a lofty statement that, upon closer inspection of Turbo Energy’s SunBox Home technical details, appears to hold up. Marketed by the company as the most complete all-in-one device on the market, SunBox packs in inverters, batteries, and…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to TURB are available in the company’s newsroom at https://ibn.fm/TURB

About TechMediaWire

TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer

TechMediaWire
Los Angeles, CA
www.TechMediaWire.com
310.299.1717 Office
[email protected]

TechMediaWire is powered by IBN

• In November 2023, the company announced a purchase order from a Romanian company for seven TRACER 1000 ETDs to be deployed in a European airport
• Astrotech announced in June 2023 that its board unanimously rejected an unsolicited acquisition proposal from BML Investment Partners
• In May 2023, the company announced a purchase order from a Romanian company for 17 TRACER 1000 ETDs, to be delivered during calendar 2023
• Astrotech confirmed test results from field trials of the AgLAB 1000-D2 mass spectrometer for hemp and cannabis producers, improving yields by an average of 24%
• In December 2022, the company effected a 1-for-30 reverse stock split, reducing the number of outstanding common shares

Astrotech (NASDAQ: ASTC) is an instrumentation company that designs, manufactures and commercializes solutions. Its solutions include mass spectrometry, process controls, chemical detectors and medical disease detection.

The company was established in 1984 and, prior to 2009, was known as SPACEHAB Inc., a NASA contractor offering technology originally developed for NASA to monitor air quality on the International Space Station. When the Space Shuttle program ended, the company focused on its satellite processing…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to ASTC are available in the company’s newsroom at https://cnw.fm/ASTC

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is powered by IBN

Clene (NASDAQ: CLNN), together with its wholly owned subsidiary Clene Nanomedicine Inc., recently provided operating highlights for its amyotrophic lateral sclerosis (“ALS”) clinical program. “In August, Clene reported a 24-month long-term data cut from the open-label extension (‘OLE’) of the RESCUE-ALS study as of July 2023, which showed a significant median survival benefit of 19.3 months in addition to a significant (p=0.049) 52% decreased risk of ALS clinical worsening events – defined as the first occurrence of death, tracheostomy (a procedure that involves creating an opening in the neck into the windpipe to help air and oxygen reach the lungs), assisted ventilation, or feeding tube placement – in patients originally treated with CNM-Au8. The data also showed a 75% decreased risk of long-term all-cause mortality,” reads a recent article. “A month later, the company reported long-term follow-up data for patients treated with CNM-Au8 for up to 133 weeks in the OLE of the HEALEY ALS platform trial. The post hoc results showed significantly improved survival compared to matched historical placebo controls from previously completed phase 2 and phase 3 ALS trials stored in the Pooled Resource Open-Access ALS Clinical Trials (‘PRO-ACT’) database, the largest U.S. clinical database of previous ALS trials.”

To view the full article, visit https://ibn.fm/kcHit

About Clene Inc.

Clene (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8(R) is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8(R) is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is planning to submit an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) in the next 45 days. The application is for the company’s planned U.S. phase 1b Hypertension Clinical Trial. The filing had been delayed for necessary documentation from a raw material supplier, which is now being provided, enabling Lexaria to finalize the IND application. According to the announcement, the supplier anticipates providing the final two pieces of outstanding information to the FDA within the next 45 days, after which Lexaria can proceed with filing the IND application. The trial, which is titled “A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DehydraTECH-CBD(TM) in Subjects with Stage 1 or Stage 2 Hypertension,” is designed to evaluate safety and tolerability in hypertensive patients. Secondary objectives of the study will include efficacy evaluation in reducing blood pressure together with detailed pharmacokinetic testing. “Lexaria feels confident, given that from 2018 through 2022 it has previously conducted five human clinical trials studying DehydraTECH-CBD in an aggregate total of 134 people, without recording a single serious adverse event, that it’s proposed phase 1b study plan will not expose test subjects to unreasonable risk,” the company stated in the press release. “Lexaria looks forward to submitting this important IND filing and hopes that the review process proceeds smoothly toward effectiveness in the subsequent 30 day period allotted by the FDA.”

To view the full press release, visit https://ibn.fm/Ne8PK

About Lexaria Bioscience Corp.

Lexaria Bioscience’s patented drug-delivery formulation and processing platform technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual property portfolio with 37 patents granted and many patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is powered by IBN

• Israel passed the Electronic Monitoring Bracelet Law in June 2023, allowing courts to monitor abusers through electronic monitoring (EM), a practice already employed in a growing number of other countries
• SuperCom’s PureSecurity Electronic Monitoring Suite has been used in other countries to monitor domestic violence offenders, including use as part of Romania’s first electronic monitoring program
• The company is seen at the forefront when it comes to advances in EM technology for domestic violence applications

In late June 2023, the Israeli government passed the Electronic Monitoring Bracelet Law, which National Security Minister Itamar Ben-Gvir proposed. The purpose of the law is to allow the court to impose monitoring of abusers through an electronic monitoring solution, which keeps the person under surveillance and monitored in real time. Israel is not the first country to use electronic monitoring devices for domestic violence offenders. Countries including Romania, Sweden, and the United States, have all used this technology to help prevent additional domestic violence cases.

SuperCom (NASDAQ: SPCB), a leading global provider of traditional and digital identity solutions, providing advanced safety, identification, and security products and solutions to governments and private and public organizations, is at the forefront of domestic violence electronic monitoring…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

About TechMediaWire

TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer

TechMediaWire
Los Angeles, CA
www.TechMediaWire.com
310.299.1717 Office
[email protected]

TechMediaWire is powered by IBN

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, is in the spotlight. Cepton senior vice president of product Brunno Moretti is the featured guest on the latest video interview from Proactive. During the segment, Moretti and Proactive host Steve Darling talked about how Cepton’s proprietary LiDAR tech is revolutionizing truck safety. Noting that the sheer size and weight of semi-trucks create challenges, Moretti explained the need for effective detection systems, especially for autonomous and advanced driver-assistance systems. Cepton’s LiDAR is capable of detecting small objects as far away as 300 meters, providing comprehensive coverage around the vehicle and protection for such large vehicles. The technology aids in other safety aspects, including preventing trailer sway and jackknifing and ensuring safe parking. During the interview, Moretti also discussed Cepton’s engagement in Request for Quote (“RFQ”) discussions with major semi companies for autonomous driving applications, noting the positive response and growing interest that the company’s LiDAR solutions are receiving. Proactive is a tech-enabled platform empowering companies globally with a comprehensive investor engagement solution across their business lifecycle. The platform works with innovative growth companies quoted on the world’s major stock exchanges, helping executives engage intelligently with investors. “As the trucking industry continues to expand, the integration of LiDAR technology is poised to play a crucial role in promoting safer transportation,” the press release stated.

To view the full Proactive interview, visit https://ibn.fm/ksrau

To view the full press release, visit https://ibn.fm/16sF8

About Cepton Inc.

Cepton is a Silicon Valley innovator of lidar-based solutions for automotive (“ADAS/AV”), smart cities, smart spaces and smart industrial applications. With its patented lidar technology, Cepton aims to take lidar mainstream and achieve a balanced approach to performance, cost and reliability, while enabling scalable and intelligent 3D-perception solutions across industries. Cepton has been awarded a significant ADAS lidar series production award with Koito on the General Motors Business. Cepton is also engaged with all top 10 global OEMs. Founded in 2016 and led by industry veterans with decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high-performance, high-quality lidar solutions. Cepton is headquartered in San Jose, California, and has a center of excellence facility in Troy, Michigan, to provide local support to automotive customers in the metro Detroit area. Cepton also has a presence in Germany, Canada, Japan, India and China to serve a fast-growing global customer base. For more information about this company, please visit www.Cepton.com.

NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

About TechMediaWire

TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer

TechMediaWire
Los Angeles, CA
www.TechMediaWire.com
310.299.1717 Office
[email protected]

TechMediaWire is powered by IBN

• SenesTech, experts in animal fertility control, posted a 44% YOY revenue growth for Q3 2023
• Gross profit also saw 49% growth from $122,000 in 2022 to $175,000 in 2023
• The growth was attributed to the company’s primary initiatives to drive sales, improve product quality, and expand product options
• The company looks to greatly accelerate growth with the launch of its Evolve Soft Bait, key to opening the huge professional rodent control market, and the first and only soft bait developed to control pest populations through technology that targets the population where it starts, without poisons

SenesTech (NASDAQ: SNES), an animal fertility control innovator and the inventor of the only EPA-registered contraceptive for male and female rats, announced its financial results for the third quarter of the 2023 financial year (“Q3, 2023”) on November 9, 2023. Of note was the 44% year-over-year (“YOY”) growth in revenue, primarily attributed to the company’s initiatives to drive sales, improve product quality, and expand product options.

“We accelerated our growth trajectory during the third quarter with strong 44% year-over-year growth in revenues driven by the initiatives we have undertaken to drive sales, improve our product quality, and expand…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has filed a spoofing complaint in the U.S. District Court for the Southern District of New York. The complaint, filed on Dec. 6, 2023, alleges that UBS Securities LLC, IMC Financial Markets and Clear Street Markets LLC engaged in a scheme using spoofing to manipulate the market price of Mullen shares. The company noted that the claim for the spoofing litigation is attached to the company’s Form 8-K, which it filed this week with the Securities and Exchange Commission (“SEC”). According to the announcement, Mullen believes that the spoofing litigation provides greater potential to recover damages based on the nature of the claims and the duration of the two-year period when the spoofing allegedly occurred. In addition, Mullen has dismissed the lawsuit it had filed in August in the U.S. District Court for the Southern District of New York; the litigation alleged that certain broker-dealers were attempting to manipulate the share price of the company’s securities focusing on short-selling claims. “My focus continues to provide transparency and to protect the long-term value for our company and our stockholders,” said Mullen CEO and chair David Michery in the press release. “We believe that the spoofing litigation provides the best opportunity to sustain our claims as well as recover damages based on the defendant’s market manipulation.”

To view the full press release, visit https://ibn.fm/gDeu8

About Mullen Automotive Inc.

Mullen Automotive is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover; the Mullen-GO Commercial Urban Delivery EV; the Mullen commercial class 1–3 EVs; and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and class 4–6 commercial offerings. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition of all Electric Last Mile Solutions (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana. To learn more about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

• The 2023 Nobel Prize in Chemistry, awarded to Moungi G. Bawendi, Louis E. Brus, and Aleksey Yekimov for their efforts in discovering and synthesizing quantum dots, recognizes the power of nanotechnology
• Nanoscience is the study of structures and molecules whose sizes range between 1 and 100 nm, while nanotechnology is the technology that utilizes nanoscience in practical applications
• The applications of nanotechnology are wide-ranging, from industrial-scale catalysis and modern electronics to precision medicine and quantum technology
• Clene Inc., a late clinical-stage biopharmaceutical company, has applied nanotechnology alongside other science concepts in the development of catalytically active nanocrystals
• The catalytic activities of the nanocrystals drive, support, and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed, and damaged cells

The Royal Swedish Academy of Sciences (“the Academy”), which is responsible for awarding Nobel Prizes in Chemistry and Physics, decided to award this year’s Nobel Prize in Chemistry to Moungi G. Bawendi, Louis E. Brus, and Aleksey Yekimov for their efforts in discovering and synthesizing quantum dots, nanometer-sized semiconductor crystals that bring colored light to TV screens with Q-LED technology (https://ibn.fm/shWLi). The 2023 Nobel Prize in Chemistry recognizes the power of nanotechnology and the importance of quantum dots in nanotechnology.

Although the origins of nanotechnology predate the trio of laureates, their work was “part of the earliest wave of modern nanotechnology where researchers began putting breakthroughs in material science to practical use,” according to Andrew Maynard, Professor of Advanced Technology Transitions at the…

Read More>>

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company focused on developing innovative therapies for central nervous system disorders, specifically aggressive brain cancers. In September, the company announced that 200 out of 243 expected patients had been enrolled in its ongoing study evaluating the effectiveness of Berubicin for recurrent glioblastoma (“GBM”), a highly aggressive and incurable form of brain cancer. The critical and adaptive global trial involves multiple centers and is open-label, randomized and controlled, comparing Berubicin to Lomustine – the standard of care – in adult patients with recurrent GBM (“WHO Grade IV”) after standard first-line therapy has failed. The company reports that its interim analysis is showing promising results. CNS Pharmaceuticals had set a specific goal to analyze the trial data after more than half of the patients enrolled in the study reached the main effectiveness measure. During this analysis, an independent review board closely examines the number of deaths in each treatment group to ensure that patients receiving Berubicin show a significant improvement in overall survival compared to those receiving Lomustine. They also review other important factors like how long patients live without the cancer progressing, response rates and safety.

To view the full press release, visit https://ibn.fm/02o07

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

SuperCom Ltd. (NASDAQ: SPCB), a global provider of secured solutions for the e-Government, IoT, and cybersecurity sectors, today announced that it has secured a new contract with a prominent Kentucky -based service provider of electronic monitoring (“EM”) products and services. The contract marks another valuable step in SuperCom’s expansion within the U.S. and progression in the deployment of its newest proprietary technologies: the new PureOne GPS bracelet and domestic violence (“DV”) monitoring solutions. “We are proud to see our new proprietary solutions gaining traction in new regions in the U.S., reaffirming our commitment to innovation and excellence in the field of electronic monitoring,” said Ordan Trabelsi, CEO and president of SuperCom. “This new contract allows us to bring our advanced technology to more communities and aid in the crucial work of domestic violence prevention and offender monitoring. It is a testament to the hard work of our team and the trust our partners place in our technology.”

To view the full press release, visit https://ibn.fm/DUhgT

About SuperCom

Since 1988, SuperCom has been a global provider of traditional and digital identity solutions, providing advanced safety, identification and security solutions to governments and organizations, both private and public, throughout the world. Through its proprietary e-Government platforms and innovative solutions for traditional and biometrics enrollment, personalization, issuance and border control services, SuperCom has inspired governments and national agencies to design and issue secure multi-ID documents and robust digital identity solutions to its citizens and visitors. SuperCom offers a unique all-in-one field-proven RFID & mobile technology and product suite, accompanied by advanced complementary services for various industries including healthcare and homecare, security and safety, community public safety, law enforcement, electronic monitoring, livestock monitoring, and building and access automation. For more information about the company, visit www.Supercom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

About TechMediaWire

TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer

TechMediaWire
Los Angeles, CA
www.TechMediaWire.com
310.299.1717 Office
[email protected]

TechMediaWire is powered by IBN

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has released a fireside chat video with CEO and chair Howard Weisman. During the company update video, Weisman outlines the company’s recent achievement and reiterates PaxMedica’s focus on developing groundbreaking therapies and transformative solutions. Specifically, Weisman provided a summary of the company’s Oct. 25, 2023, FDA Type-B meeting, including the regulatory pathway for HAT-PAX-101. He also discussed the company’s successful $7 million public offering and the recent acquisition of suramin research assets from Rediscovery Life Sciences (“RLS”) as well as provided updates on the phase 3 trial for HAT-PAX-101 and plans for future autism spectrum disorder (“ASD”) trials. In addition, Weisman explained PaxMedica’s business strategy, placing particular emphasis on efficiency, production milestones and key partnerships, and the company’s future vision, including NDA plans for PAX-101 and potential advancements in autism treatment.

To view the full video, visit https://ibn.fm/yUe3j

To view the full press release, visit https://ibn.fm/OPrkh

About PaxMedica Inc.

PaxMedica is a forward-looking, clinical-stage biopharmaceutical firm specializing in cutting-edge, anti-purinergic drug therapies (“APT”) aimed at addressing a range of challenging neurologic disorders. The company’s comprehensive portfolio encompasses a spectrum of conditions, including neurodevelopmental disorders such as autism spectrum disorder (“ASD”) as well as other critical areas within the neurology field. PaxMedica is dedicated to the continuous development and evaluation of its pioneering program, PAX-101, an intravenous suramin formulation that lies at the heart of the company’s efforts, particularly focused on innovative ASD treatment solutions. The company’s ongoing research initiatives not only prioritize the needs of ASD patients but also extend to exploring potential therapeutic applications for related conditions. For more information about the company, visit www.PaxMedica.com.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced its filing of a complaint in the United States District Court for the Southern District of New York alleging that UBS Securities, LLC, IMC Financial Markets and Clear Street Markets, LLC (the “Defendants”) engaged in a market manipulation scheme that violated Section 10(b) and Rule 10b-5(a) and (c) and Section 9(a) of the Securities Exchange Act of 1934. The lawsuit alleges that between Nov. 9, 2021, and Nov. 9, 2023, the Defendants and/or their customers used spoofing to manipulate the market price of Mullen shares. “In the 21 years our team has been prosecuting market manipulation cases against Wall Street, I believe this could be one of the largest and strongest spoofing and market manipulation cases we have handled,” said Wes Christian of Christian Attar Group. “After working with our consulting and investigative experts, I believe the damage model could be in the billions of dollars.”

To view the full press release, visit https://ibn.fm/V0GvN

About Mullen Automotive Inc.

Mullen is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover, Mullen-GO Commercial Urban Delivery EV, Mullen Commercial Class 1-3 EVs and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and Class 4-6 commercial offerings. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition of Electric Last Mile Solutions’ (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana. For more information about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

Turbo Energy (NASDAQ: TURB), a leading photovoltaic energy storage technology company based in Valencia, Spain, today announced that it has selected IBN, a multifaceted financial news and publishing company for private and public entities, to assist with its corporate communications initiatives. Turbo Energy designs, develops and distributes equipment for the generation, management and storage of photovoltaic energy in Spain, Europe and internationally. The company recently launched its flagship product, the Sunbox, an all-in-one device that integrates most of the equipment required for a residential photovoltaic installation. Powered by AI, the Sunbox features a software system that monitors the generation, use and management of photovoltaic energy by analyzing large amounts of data related to energy generation, consumption, market prices and weather forecasts. As part of the client partner relationship, IBN will generate greater awareness for Turbo Energy by leveraging its investor based distribution network of 5,000+ key syndication outlets, various newsletters, social media channels, wire services via InvestorWire, blogs and other outreach tools.

To view the full press release, visit https://ibn.fm/ftaWV

About Turbo Energy S.A.

Turbo Energy is a leading photovoltaic energy storage technology company based in Valencia, Spain. The company’s focus is on developing innovative solutions that allow end consumers to harness the full potential of solar energy and reduce their electricity costs. With a combination of artificial intelligence and advanced technology, Turbo Energy is paving the way toward a more sustainable and energy-efficient future. For more information, visit the company’s website at www.Turbo-E.com.

NOTE TO INVESTORS: The latest news and updates relating to TURB are available in the company’s newsroom at https://ibn.fm/TURB

About GreenEnergyStocks

GreenEnergyStocks (“GES”) is a specialized communications platform with a focus on companies working to shape the future of the green economy. GreenEnergyStocks is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, GES is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, GES brings its clients unparalleled recognition and brand awareness. GES is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from GreenEnergyStocks, text “Green” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenEnergyStocks.com

Please see full terms of use and disclaimers on the GreenEnergyStocks website applicable to all content provided by GES, wherever published or re-published: https://www.greennrgstocks.com/Disclaimer

GreenEnergyStocks
Los Angeles, CA
www.GreenEnergyStocks.com
310.299.1717 Office
[email protected]

GreenEnergyStocks is powered by IBN

SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal pest populations, is in the spotlight during a recent episode of The Stock2Me Podcast. Hosted by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, the podcast is part of a sustained effort to provide specialized content distribution via widespread syndication channels. The latest episode features SenesTech CEO and president Joel Fruendt, who joins host Stuart Smith to talk about the company’s business model and recent operation highlights. During the interview, Fruendt explains that SenesTech is a biotech and life sciences company focused on developing, patenting and commercializing product formulations for fertility control of animal pests. “We’re addressing one of the world’s oldest and most challenging problems, and that’s rodent control,” said SenesTech CEO and president Joel Fruendt during the interview. “We’re doing this through a completely different way than has ever been done before by addressing the root cause of the problem, which is reproduction. Traditional pest control tools like poisons seek to control the death rate. They’re just very reactive. The challenge is the incredible rate of reproduction of the rat. Given sufficient food, water and harborage, which most cities have, two breeding rats can result in 15,000 offspring after a single year. You cannot poison them or trap them or gas them fast enough to overcome their fertility. You need to control the population by reducing the birth rate, and that is our why. . . . Our solution is an effective, humane and environmentally friendly way of controlling this animal pest population through fertility control, and once you control the population, other tools in the integrated pest management toolbox then become much more effective.”

To view the full episode, visit https://ibn.fm/TjdFZ

To view the full press release, visit https://ibn.fm/rUCVh

About SenesTech Inc.

SenesTech is committed to improving the health of the world by humanely managing animal pest populations through fertility control. The company is expert in fertility control to manage animal pest populations. SenesTech invented ContraPest, the only U.S. EPA-registered contraceptive for male and female rats, and Evolve, an EPA-designated minimum risk contraceptive currently offered for rats. ContraPest and Evolve fit seamlessly into all integrated pest-management programs, significantly improving the overall goal of effective pest management. The company strives for clean cities, efficient businesses and happy households by providing a product designed to be humane, effective and sustainable. For more information about the company, please visit www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES

About TechMediaWire

TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer

TechMediaWire
Los Angeles, CA
www.TechMediaWire.com
310.299.1717 Office
[email protected]

TechMediaWire is powered by IBN

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, is spotlighted in a recent Proactive interview. During the interview, Cepton chief commercial officer Mitch Hourtienne and Proactive host Steve Darling talked about LiDAR technology, with Hourtienne specifically clarifying misconceptions and explaining the categories of deals in the automotive sector related to LiDAR adoption. Hourtienne provided an overview of Cepton’s progress, including successful hardware validation and software milestones; he also addressed the company’s ongoing focus on both hardware and software development, emphasizing Cepton’s commitment to advancing LiDAR technology in the auto industry. During the interview, Hourtienne also discussed the company’s R&D partnerships and noted design wins as well as production awards where vehicle models commit to funding LiDAR within a given timeframe. When Darling asked about the time-consuming process of integrating LiDAR into vehicles, Hourtienne compared it to the evolution of cameras and radar on automobiles, observing that he expects LiDAR will initially be available on luxury vehicles before becoming more widespread for an array of applications. Hourtienne also touched on Cepton’s collaboration with both Koito Manufacturing and General Motors, focusing on hardware installation, power consumption and software integration to optimize LiDAR for vehicles.

To view the full interview, visit https://ibn.fm/4G1hz

To view the full press release, visit https://ibn.fm/0Yi08

About Cepton Inc.

Cepton is a Silicon Valley innovator of lidar-based solutions for automotive (“ADAS/AV”), smart cities, smart spaces and smart industrial applications. With its patented lidar technology, Cepton aims to take lidar mainstream and achieve a balanced approach to performance, cost and reliability, while enabling scalable and intelligent 3D-perception solutions across industries. Cepton has been awarded a significant ADAS lidar series production award with Koito on the General Motors business. Cepton is also engaged with all top 10 global OEMs. Founded in 2016 and led by industry veterans with decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high-performance, high-quality lidar solutions. Cepton is headquartered in San Jose, California, and has a center of excellence facility in Troy, Michigan, to provide local support to automotive customers in the metro Detroit area. Cepton also has a presence in Germany, Canada, Japan, India and China to serve a fast-growing global customer base. For more information about this company, please visit www.Cepton.com.

NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

About TechMediaWire

TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer

TechMediaWire
Los Angeles, CA
www.TechMediaWire.com
310.299.1717 Office
[email protected]

TechMediaWire is powered by IBN

• Lexaria, a global innovator in drug delivery platforms, just announced additional positive interim results from its ongoing GLP-1 human pilot study
• The study seeks to provide an early-stage indication of whether DehydraTECH(TM) processing could improve oral drug delivery characteristics of the GLP-1 drug semaglutide
• Lexaria’s DehydraTECH GLP-1 showed a 2.9% to 14.6% blood glucose level reduction relative to baseline, compared to 1.3% to 6.7% for the control group
• The DehydraTECH GLP-1 group also only saw a 5.3% spike in glucose levels after having a standardized meal at the 240-minute mark and a snack at the 360-minute mark, compared to 22.7% for the control group

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced additional positive interim results from its ongoing human pilot study that seeks to provide an early-stage indication of whether DehydraTECH(TM) processing could improve oral drug delivery characteristics of the GLP-1 drug semaglutide. The study, which focused on Rybelsus(R), a commercially available semaglutide drug, involved seven healthy subjects, four of whom received the DehydraTECH GLP-1, with the other three receiving the control (https://cnw.fm/kr4Ic).

Of note was DehydraTECH GLP-1’s 2.9% to 14.6% blood glucose level reduction relative to baseline, compared to 1.3% to 6.7% for the control group. These results were achieved in the initial 100 minutes of taking the drugs, and at all but the 20-minute and 240-minute sample time points, the DehydraTECH…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is powered by IBN

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has delivered its All-Electric Class 3 EV, the Mullen THREE, to the Randy Marion Automotive Group (“RMA”) in North Carolina. Mullen’s retail dealership partner, RMA is one of the largest commercial fleet dealers in the United States. The Mullen THREE is a low-cab forward chassis truck assembled in Mullen’s Mississippi-based commercial vehicle assembly plant. The newest Mullen vehicle boasts a 5,800-plus pound payload and 130-mile range and is specifically designed for the “urban last-mile delivery.” The truck chassis can be customized to meet a variety of vocational needs, including last-mile delivery, construction, landscaping, catering and more. “We are in full swing delivery of Class 3 vehicles to Randy Marion Automotive Group in North Carolina,” said Mullen Automotive CEO David Michery in the press release. “It’s exciting to see a constant flow of vehicle transports picking up Class 3’s at our Tunica assembly plant and heading down the road for customer deliveries.”

To view the full press release, visit https://ibn.fm/NSlHG

About Mullen Automotive Inc.

Mullen Automotive is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover; the Mullen I-GO Commercial Urban Delivery EV; the Mullen commercial class 1–3 EVs; and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and class 4–6 commercial offerings. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition of Electric Last Mile Solutions (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana. To learn more about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

• PaxMedica’s total gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses, were approximately $7 million
• The company intends to use the proceeds to pay an outstanding promissory note, advance development programs, and general corporate purposes
• PaxMedica received constructive feedback from its type-B meeting with the FDA, which will aid in completing the remaining paperwork necessary to file a New Drug Application
• The company is currently working on commercial lots of PAX-101, which are expected during the first half of 2024, for the New Drug Application, which is expected to be filed during the second half of 2024

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of Autism Spectrum Disorder (“ASD”) and other serious conditions with intractable neurologic symptoms, recently reported the closing of its public offering. PaxMedica’s total gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses, were approximately $7 million. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering (https://ibn.fm/XEIiL).

The previously announced public offering is an aggregate of 5,384,615 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 5,384,615 shares of common stock at a public offering price of $1.30 per share and accompanying warrant. The warrants have an…

Read More>>

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal pest populations, today announced that its ContraPest(R) products have been registered for sale and immediate use in Puerto Rico. The first and only EPA-registered rat contraceptive impacting both male and female rats, ContraPest fits seamlessly into all integrated pest management programs, significantly improving the overall goal of effective pest management. “Puerto Rico, as an island nation, is ideally positioned to benefit from ContraPest’s unique fertility control features. Similar to many other islands, rats in Puerto Rico have posed a huge problem for society, whether it be food contamination or destruction, infrastructure damage or public health risks,” said Joel Fruendt, SenesTech president and CEO. “The grain industry, in particular, has been hit hard by rat infestations, endangering food security for the island. We are currently finalizing plans with a large agricultural firm to be our lead customer in the country.”

To view the full press release, visit https://ibn.fm/dsA2L

About SenesTech Inc.

SenesTech is committed to improving the health of the world by humanely managing animal pest populations through fertility control. The company is an expert in fertility control to manage animal pest populations. It invented ContraPest(R), the only U.S. EPA-registered contraceptive for male and female rats, and Evolve(TM), an EPA-designated minimum risk contraceptive currently offered for rats. ContraPest and Evolve fit seamlessly into all integrated pest management programs, significantly improving the overall goal of effective pest management. SenesTech strives for clean cities, efficient businesses and happy households – with a product designed to be humane, effective and sustainable. For more information about the company, visit www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES

About TechMediaWire

TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer

TechMediaWire
Los Angeles, CA
www.TechMediaWire.com
310.299.1717 Office
[email protected]

TechMediaWire is powered by IBN

Vision Marine Technologies (NASDAQ: VMAR), a global leader and innovator within the performance electric recreational boating industry, is partnering with Blue Water Boat Rental to expand into Riviera Beach, Florida. The company’s new operation is a “key milestone” in a strategic plan to broaden the reach and impact of sustainable electric boating. VMAR’s new Riviera Beach location, which is located near Peanut Island and benefits from Florida’s year-round boating climate, is scheduled to open this month. In a first for the company, the location will offer the revolutionary E-Motion(TM) 180E Powertrain System to renters. A leader in internal combustion engine boat rentals, Blue Water Boat Rental and its management noted that while other companies have thought about the idea of electric propulsion, Vision Marine has “actually developed and produced the technology that made this idea a reality.” The “win-win-win” situation for Blue Water, Vision Marine and customers will allow boat enthusiasts to try out this new technology before buying their own electric outboard or boat. Vision Marine offers a range of popular boat options outfitted with its advanced 180E E- Motion Powertrain, including center-console boats, bowriders and pontoons. The company, which has locations on the West Coast, is focused on growing its fleet to 25 diverse boats that blend high-performance E-Motion-equipped models with traditional offerings. “The opening of our first rental operation in Florida this month marks a significant milestone in our quest to transform the boating industry, and this is just the beginning,” said Vision Marine Technologies CEO Alexandre Mongeon in the press release.

To view the full press release, visit https://ibn.fm/c1dmB

About Vision Marine Technologies Inc.

Vision Marine Technologies strives to be a guiding force for change and an ongoing driving factor in fighting the problems associated with waterway pollution by disrupting the traditional boating industry with electric power, in turn directly contributing to zero pollution, zero emission and a noiseless environment. The company’s Flagship E-Motion 180E electric marine powertrain is the first fully electric, purpose-built outboard powertrain system that combines an advanced battery pack, inverter and high-efficiency motor with proprietary union assembly between the transmission and the electric motor design utilizing extensive control software. VMAR’s E-Motion(TM) and related technologies used in this powertrain system are uniquely designed to improve the efficiency of the outboard powertrain and, as a result, enhance both range and performance. Vision Marine continues to design, innovate, manufacture and sell handcrafted, environmentally friendly, electric recreational boats to customers. The design and technology applied to its boats results in far greater enhanced performance in general, higher speeds and longer range. Simply stated, a smoother ride than a traditional internal combustion engine (“ICE”) motorboat. For more information about the company, please visit www.VisionMarineTechnologies.com.

NOTE TO INVESTORS: The latest news and updates relating to VMAR are available in the company’s newsroom at http://ibn.fm/VMAR

About TinyGems

TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, CA
www.TinyGems.com
310.299.1717 Office
[email protected]

TinyGems is powered by IBN

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, is spotlighted in a recent H.C. Wainwright & Co. research report. The report “is initiating coverage on PaxMedica, an emerging firm developing novel formulations of suramin for treatment of neurological disorders with intractable symptoms,” which is “attacking autism with a novel approach.” The report noted that PaxMedica was the first company to design and execute a controlled clinical study based on the agency’s inputs, with top-line data based on retrospective analysis of medical records being presented in November 2023 that “showed PAX-101 (intravenous suramin) clinical meaningfulness in S1 TBR HAT, suggesting clinical derisking was achieved.” The report stated that the company is planning to file a New Drug Application (“NDA”) next year that will make PaxMedica eligible to receive a Priority Review Voucher (“PRV”) that could be sold for more than $100 million if approved. “We have assessed PaxMedica using a discounted cash flow -based valuation methodology, which ascribes an 11% discount rate and 2% terminal rate of decline to the company’s future cash flows,” the report states.

“In our view, these parameters appropriately define the risk associated with the company’s PAX-101 program in [autism spectrum disorder] (‘ASD’), while also taking into account the future generic erosion that may occur at the end of the lifespan of PaxMedica’s intellectual property estate. We also utilize a 30% probability of approval for PAX-101 in ASD, which reflects the well-characterized nature of suramin as a compound with a long history of usage in human subjects as well as the proof-of-concept data from earlier-stage studies in patients with autism. Our assumptions derive a $60M total risk-adjusted value for PAX-101. This yields a 12-month price objective of $3 per share, assuming roughly 19.2M fully-diluted shares outstanding as of end-2024. . . . Our rating is Buy with a 12-month price target of $3 per share.”

To view the full research report, visit https://ibn.fm/XMAnK

About PaxMedica Inc.

PaxMedica is a forward-looking, clinical-stage biopharmaceutical firm specializing in cutting-edge, anti-purinergic drug therapies (“APT”) aimed at addressing a range of challenging neurologic disorders, including autism spectrum disorder (“ASD”) and human African trypanosomiasis (“HAT”). The company’s portfolio encompasses critical areas within the neurology field, with a focus on pioneering advancements in both ASD and HAT treatments. PaxMedica is dedicated to the continuous development and evaluation of its pioneering program, PAX-101, an intravenous suramin formulation that lies at the heart of the company’s efforts, particularly focused on innovative ASD and HAT treatment solutions. The company’s ongoing research initiatives not only prioritize the needs of ASD and HAT patients but also extend to exploring potential therapeutic applications for related conditions. For more information about the company, visit www.PaxMedica.com.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced that it has hired Mark R. Basile, Esq. and his law firm, The Basile Law Firm P.C., to assist the company in reviewing its current fundings and to make recommendations in developing its floorplan for future fundings. “Mullen is committed to full transparency to the public markets. We are making this announcement in an effort to notify our shareholders that we fully intend to take any and all measures necessary to continue our sustainable growth as we move ahead with previously announced strategic initiatives,” said David Michery, CEO and chairman of Mullen Automotive. “Mark R. Basile, Esq. is a former law professor and a well-known and respected securities litigator. Mr. Basile is also known for helping public companies improve their internal operations and to recommend board and company initiatives. We welcome Mr. Basile to our team of highly skilled and capable lawyers, both in-house and out, and we are looking forward to working with him as we continue to drive our core business value forward.”

To view the full press release, visit https://ibn.fm/hqYmF

About Mullen Automotive Inc.

Mullen is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover, Mullen-GO Commercial Urban Delivery EV, Mullen Commercial Class 1-3 EVs and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and Class 4-6 commercial offerings. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition of Electric Last Mile Solutions’ (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana. For more information about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

Turbo Energy (NASDAQ: TURB) designs, develops and distributes equipment for the generation, management and storage of photovoltaic energy in Spain, Europe and internationally. “Turbo Energy’s products include lithium-ion batteries and inverters. Additionally, the company recently launched its flagship product, the Sunbox, an all-in-one device that integrates most of the equipment required for a residential photovoltaic installation. The Sunbox is powered by AI and features a software system that monitors the generation, use and management of photovoltaic energy by analyzing large amounts of data related to energy generation, consumption, market prices and weather forecasts. This AI system optimizes battery usage, reducing electricity bills and providing peak-use reduction and uninterruptible power supply functions. Turbo Energy currently sells its photovoltaic energy equipment primarily through distributors for residential consumers in Spain, but it possesses the expertise and international perspective to expand its product portfolio into industrial and commercial scale and markets, as well as advancing the internationalization process it has already started,” a recent article reads. “Turbo Energy is one of the leading companies that introduced lithium-ion batteries for photovoltaic energy storage in Spain. Primarily for the home energy storage market, the company’s batteries have capacities from 2.24 kWh to 5.1 kWh in 24 and 48 volts. In addition, its 48V / 5.1 kWh units are available in a dual battery system.”

To view the full article, visit https://ibn.fm/HuQ4B

About Turbo Energy S.A.

Turbo Energy is a leading photovoltaic energy storage technology company based in Valencia, Spain. The company’s focus is on developing innovative solutions that allow end consumers to harness the full potential of solar energy and reduce their electricity costs. With a combination of artificial intelligence and advanced technology, Turbo Energy is paving the way towards a more sustainable and energy-efficient future. For more information, visit the company’s website at www.Turbo-e.com.

NOTE TO INVESTORS: The latest news and updates relating to TURB are available in the company’s newsroom at https://ibn.fm/TURB

About GreenEnergyStocks

GreenEnergyStocks (“GES”) is a specialized communications platform with a focus on companies working to shape the future of the green economy. GreenEnergyStocks is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, GES is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, GES brings its clients unparalleled recognition and brand awareness. GES is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from GreenEnergyStocks, text “Green” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenEnergyStocks.com

Please see full terms of use and disclaimers on the GreenEnergyStocks website applicable to all content provided by GES, wherever published or re-published: https://www.greennrgstocks.com/Disclaimer

GreenEnergyStocks
Los Angeles, CA
www.GreenEnergyStocks.com
310.299.1717 Office
[email protected]

GreenEnergyStocks is powered by IBN

• D-Wave recently shared important research results demonstrating successful quantum error mitigation (“QEM”) in its Advantage2(TM) annealing quantum computing experimental prototype
• The company’s latest research focuses on zero-noise extrapolation, one of the most practical QEM techniques, maintaining the quantum state and reducing errors
• D-Wave has also made significant progress with high-coherence fluxonium qubits, setting new standards in quantum properties

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, and the world’s first commercial supplier of quantum computers, recently shared important research results that demonstrate successful quantum error mitigation (“QEM”) in its Advantage2(TM) annealing quantum computing experimental prototype. This progress in reducing errors in quantum computers is expected to drive performance advancements in the company’s future quantum computing systems and processors.

Quantum computing is incredibly powerful but can be sensitive to noise and imperfections in the hardware – known as “errors.” Fixing these errors is a major challenge, and while there is a solution called quantum error correction, it’s currently too complex and resource-intensive to be…

Read More>>

Forward-Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this press release include, but are not limited to, statements regarding the potential impact and results of D-Wave’s progress in QEM; the new possibilities that may result from successful QEM including simulating exotic materials and moving closer to quantum supremacy on D-Wave processors; the potential impact of D-Wave’s work with fluxonium qubits on D-Wave’s hardware development and technical leadership. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the possibility for research results to differ in the future from what has been recorded to date; general economic conditions and other risks; D-Wave’s ability to expand its customer base and the customer adoption of its solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against the company; risks related to the performance of D-Wave’s business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of D-Wave’s products; the effects of competition on the company’s business; the risk that the company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the company may never achieve or sustain profitability; the risk that the company is unable to secure or protect its intellectual property; volatility in the price of its securities; the risk that D-Wave’s securities will not maintain the listing on the NYSE; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. D-Wave undertakes no duty to update this information unless required by law.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, in October announced topline results from its phase 2a CLEAR MIND trial, investigating Lomecel-B(TM) for the treatment of mild Alzheimer’s disease (“AD”). “Lomecel-B(TM) is an allogeneic medicinal signaling cell (‘MSC’). MSCs appear to possess anti-inflammatory, pro-vascular and pro-regenerative properties. The study met its primary safety endpoint across all study groups based on statistical and medical assessments, with the safety data consistent with an established safety profile with no incidence of hypersensitivity, no cases of Alzheimer Related Imagine Abnormalities (‘ARIA’), no clinically asymptomatic microhemorrhages, and no notable changes in laboratory evaluations and electrocardiogram (‘ECG’) reported. Moreover, the study revealed statistically significant improvements in the secondary endpoint Composite Alzheimer’s Disease Score (‘CADS’) for Lomecel-B(TM) and specific components of the CADS,” a recent article reads. “These study results with Lomecel-B(TM) are encouraging,” Dr. Jeffrey Cummings, MD, vice chair of research at UNLV’s Department of Brain Health, is quoted as saying. “The study met its primary safety endpoint and is supported by lack of deterioration in cognitive or atrophy signals. The efficacy observations are encouraging, and these results should be used as a foundation for further studies.”

To view the full article, visit https://ibn.fm/We2Sy

About Longeveron Inc.

Longeveron is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The company’s lead investigational product is Lomecel-B(TM) an allogeneic medicinal signaling cell (“MSC”) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B(TM) has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently advancing Lomecel-B(TM) through clinical trials in three indications: hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-related Frailty. Additional information about the company is available at www.Longeveron.com.

NOTE TO INVESTORS: The latest news and updates relating to LGVN are available in the company’s newsroom at http://ibn.fm/LGVN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

• In November 2023, Vision Marine filed with the SEC to sell 370,000 ordinary shares priced at $4.05 in a private placement
• The company in November 2023 reported its receipt of a purchase order from boat manufacturer Wired Pontoons for 25 units of its E-Motion 180E powertrain system
• Vision Marine announced in October 2023 delivery of E-Motion 180E powertrain technology to boat manufacturer Groupe Beneteau, to be integrated on the Four Winns H2e Bowrider model
• In August 2023, a catamaran powered by a Vision Marine powertrain set an electric boat world speed record of 116 mph at the Lake of the Ozarks Shootout in Missouri
• The company raised $27 million in a December 2020 U.S. initial public offering

Vision Marine Technologies (NASDAQ: VMAR) is a global leader and innovator within the performance electric recreational boating industry. The company is engaged in designing and manufacturing electric outboard powertrain systems and related technology. It strives to be a guiding force for change and an ongoing driving factor in fighting the problems associated with waterway pollution by disrupting the traditional boating industry with electric power, in turn directly contributing to zero pollution, zero emission and a noiseless environment.

Vision Marine manufactures hand-crafted, highly durable, low maintenance, environmentally friendly electric recreational powerboats. The company’s business segments include the sale and rental of…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to VMAR are available in the company’s newsroom at https://ibn.fm/VMAR

About TechMediaWire

TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer

TechMediaWire
Los Angeles, CA
www.TechMediaWire.com
310.299.1717 Office
[email protected]

TechMediaWire is powered by IBN

• Lexaria, a global innovator in drug delivery platforms, has, through its patented DehydraTECH(TM) technology, proven to enhance the performance of several categories of fat-soluble active molecules and drugs
• Since 2018, human clinical studies on the technology have yielded positive results, ultimately earning Lexaria 37 granted patents globally, with many more pending around the world
• With the strides made so far, Lexaria looks to grow its revenue and commercial opportunities through licensing

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, remains committed to its mission to provide healthier delivery methods of drugs and other Active Pharmaceutical Ingredients (“APIs”). This is made possible through its patented drug delivery technology, DehydraTECH(TM), proven to enhance the performance of several categories of fat-soluble active molecules and drugs across oral and/or topical product formats.

The company’s efforts have focused on several key segments, including hypertension, diabetes, antivirals, epilepsy, nicotine replacement, and more. This has been an ongoing process since 2016, with positive results achieved from various clinical studies thus far, showing up to 17x brain absorption improvements…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (“CBDW”) is a specialized communications platform with a focus on CBD related news and updates in the cannabidiol (“CBD”) sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled recognition and brand awareness.

CBDW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CBDWire, text “CBDWire” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://www.CBDWire.com/Disclaimer

CBDWire
Denver, CO
www.CBDWire.com
303.498.7722 Office
[email protected]

CBDWire is powered by IBN

SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal pest populations, has closed on its previously announced public offering. According to the announcement, the offering was comprised of 3,846,154 shares of its common stock (or prefunded warrants in lieu thereof) and accompanying Series D warrants to purchase up to 3,846,154 shares of its common stock (Series D warrants) and Series E warrants to purchase up to 3,846,154 shares of its common stock (Series E warrants, together with Series D warrants, collectively the series warrants); the shares were offered at a combined offering price of $1.30 per share. The announcement noted that the series warrants, which have an exercise price of $1.30 per share, are exercisable upon issuance, while the Series D warrants will expire five years following the initial exercise date and the Series E Warrants will expire 18 months following the initial exercise date. Gross proceeds from the offering totaled an estimated $5 million before the deduction of standard fees and offering expenses. SenesTech plans to use the proceeds from the offering for general corporate purposes, including R&D, capital expenditures, working capital and general and administrative expenses, as well as potential acquisitions or investments.

To view the full press release, visit https://ibn.fm/rtvM3

About SenesTech Inc.

SenesTech is committed to improving the health of the world by humanely managing animal pest populations through fertility control. The company is expert in fertility control to manage animal pest populations. SenesTech invented ContraPest, the only U.S. EPA-registered contraceptive for male and female rats, and Evolve, an EPA-designated minimum risk contraceptive currently offered for rats. ContraPest and Evolve fit seamlessly into all integrated pest-management programs, significantly improving the overall goal of effective pest management. The company strives for clean cities, efficient businesses and happy households by providing a product designed to be humane, effective and sustainable. For more information about the company, please visit www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES

About TechMediaWire

TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer

TechMediaWire
Los Angeles, CA
www.TechMediaWire.com
310.299.1717 Office
[email protected]

TechMediaWire is powered by IBN

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced the launch of INM-089, a cannabinol (“CBN”) analog, to investigate its effects in the treatment of age-related macular degeneration (“AMD”). INM-089 is InMed Pharmaceuticals’ second ocular pharmaceutical program. “We are very pleased that this research has led to the identification of a lead CBN analog candidate to advance to additional in vivo studies as part of the preclinical development program,” said InMed’s scientific advisor, Dr. Mauro Maccarrone. “Early studies show promising neuroprotective effects of INM-089, leading to the preservation of the retinal function at the back of the eye. Neuroprotection in AMD remains an unmet medical need and a new treatment option may help solve this multifactorial disease.”

To view the full press release, visit https://ibn.fm/jwXIC

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. The company also has significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. For more information, visit www.InMedPharma.com and www.BayMedica.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is reporting additional positive interim results from its human pilot study evaluating DehydraTECH(TM) technology for the oral delivery of the glucagon-like peptide-1 (“GLP-1”) drug semaglutide, available commercially as Rybelsus(R). According to the report, DehydraTECH-powered semaglutide sustained lower levels of blood glucose from baseline including nearly 10 times lower after 24 hours as well as lower blood-glucose spikes after eating. The company noted that this was the first-ever DehydraTECH test with a “large molecule” drug. According to the report, the study was conducted by a prominent university research center comparing a single 7 mg semaglutide dose of a Rybelsus tablet (the control dose) to a matching dose from Rybelsus that had been compound formulated in capsule form using Lexaria’s DehydraTECH processing technology enhancements. Specifically, the control group showed reduced blood glucose levels by between 1.3% and 6.7% relative to the time zero baseline during the first 100 minutes of the study with the DehydraTECH GLP-1 group indicating reduced blood glucose levels by between 2.9% and 14.6% relative to baseline during that same timeframe; the report noted that even 24 hours after dose administration, the blood glucose levels were reduced in the DehydraTECH GLP-1 group by 6.3% relative to baseline while the blood glucose level evidenced in the control group was only reduced by 0.67%, evidencing nearly a tenfold improvement with the DehydraTECH GLP-1. DehydraTECH is a patented drug delivery formulation and processing platform technology. Lexaria developed the technology and is evaluating it for a variety of beneficial molecules. The formulation is designed to improve the way active molecules enter the bloodstream upon oral ingestion.

To view the full press release, visit https://cnw.fm/wPg4P

About Lexaria Bioscience Corp.

Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 37 patents granted and many patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is powered by IBN

SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal pest populations, has launched its Evolve(TM) Soft Bait product at Ace Hardware franchise locations in California; the franchise also began selling SenesTech’s Isolate(TM) bait system. According to the announcement, this is the first time a traditional retail store has carried SenesTech rodent fertility control solutions. Evolve is the first and only soft bait product featuring breakthrough, next-generation technology designed to decrease rodent populations through nonlethal methods. “California-based Scarborough Ace Hardware, as well as Scarborough Home and Garden, are the first retail outlets to commit to SenesTech’s line,” said SenesTech president and CEO Joel Fruendt in the press release. “They will also be among the first in the U.S. to receive shipments of Evolve based on their recent preorder. We expect the penetration of retail and big box to rapidly accelerate, especially with the launch of Evolve and its retail-friendly soft bait profile and packaging. Evolve was developed to offer customers a soft bait product that has similar efficacy to ContraPest but in a format that is easier to deploy, and is ideally suited for use by do it yourself consumers. We are pleased to be partnering with the team at Scarborough Ace Hardware to provide their customers with an innovative solution to address their rodent issues.”

In addition, SenesTech also announced the pricing of its public offering. According to the announcement, the offering is comprised of 3,846,154 shares of its common stock (or prefunded warrants in lieu thereof) and accompanying Series D warrants to purchase up to 3,846,154 shares of its common stock (Series D warrants) and Series E warrants to purchase up to 3,846,154 shares of its common stock (Series E warrants, together with Series D warrants, collectively the series warrants). The offering is at a combined price of $1.30 per share of common stock (or prefunded warrant in lieu thereof) and associated series warrants. The announcement noted that the series warrants, which will be immediately exercisable upon issuance, have an exercise price of $1.30 per share. Series D warrants will expire five years following the initial exercise date with Series E warrants set to expire 18 months following the initial exercise date. The public offering should close on or about Nov. 30, 2023, and is subject to customary closing conditions. Gross proceeds from the offering are anticipated to total an estimated $5 million before standard agent’s fees and other offering expenses are deducted. SenesTech plans to use the proceeds from the offering for general corporate purposes, including R&D, capital expenditures, working capital and general and administrative expenses, as well as potential acquisitions or investments.

To view the full press release, visit https://ibn.fm/EVKvz and https://ibn.fm/uFpGE

About SenesTech Inc.

SenesTech is committed to improving the health of the world by humanely managing animal pest populations through fertility control. The company is expert in fertility control to manage animal pest populations. SenesTech invented ContraPest, the only U.S. EPA-registered contraceptive for male and female rats, and Evolve, an EPA-designated minimum risk contraceptive currently offered for rats. ContraPest and Evolve fit seamlessly into all integrated pest-management programs, significantly improving the overall goal of effective pest management. The company strives for clean cities, efficient businesses and happy households by providing a product designed to be humane, effective and sustainable. For more information about the company, please visit www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES

About TechMediaWire

TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer

TechMediaWire
Los Angeles, CA
www.TechMediaWire.com
310.299.1717 Office
[email protected]

TechMediaWire is powered by IBN

• SuperCom, a global leading provider of traditional and digital identity solutions, just reported a 550% growth in EBITDA and a 74% growth in gross profit margin for Q3 2023
• Gross profit also saw an 89% YOY growth, and revenue YOY increased to $6.8 million from $6.3 million
• Ordan Trabelsi, SuperCom’s President and CEO, attributed impressive performance to the company’s successful execution of its growth strategy

SuperCom (NASDAQ: SPCB), a global leading provider of traditional and digital identity solutions offering advanced safety, identification, and security solutions to governments, just released its financial and operating results for the third quarter of the 2023 financial year (“Q3 2023”). Of note was the 550% growth in EBITDA and a 74% growth in gross profit margins that Ordan Trabelsi, SuperCom’s President and CEO, attributed to the “Successful execution of SuperCom’s growth strategy” (https://ibn.fm/4lm4s).

Revenue for Q3 2023 stood at $6.8 million, up from $6.3 million in Q3 2022. Gross profit saw an 89% year-over-year (“YOY”) growth to $4.0 million from $2.1 million in 2022, while operating income improved by 200% to $0.8 million, up from a $0.8 million operating loss the previous…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

About TechMediaWire

TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer

TechMediaWire
Los Angeles, CA
www.TechMediaWire.com
310.299.1717 Office
[email protected]

TechMediaWire is powered by IBN

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced that the company and Rapid Response Defense Systems (“RRDS”) have filed responses for final ruling and compliance by the U.S. Customs and Border Protection (“CBP”) application for Mullen’s Class 1 EV cargo van. In March 2023, the companies announced a partnership with RRDS, one of the country’s leading small business federal contractors, selecting Mullen as exclusive provider of Class 1 EV cargo vans. On behalf of Mullen, RRDS filed the Ruling Request Application, which details the substantial transformation Mullen completed for the Class 1 EV cargo van to meet U.S. Federal Motor Vehicle Safety Standards and Environmental Protection Agency regulations, which includes the design, testing and validation of new safety systems including airbags, sensors and control modules, rearview camera, front bumper system, wiring harnesses and seating. Through successful completion of the substantial transformative process, the Mullen ONE will be defined as a U.S.-made end product. “Upon a successful ruling, Mullen will have demonstrated the commitment it has made to growing the EV market in the U.S.,” said David Michery, CEO and chairman of Mullen Automotive. “Along with that I am proud to be able to say, ‘An American product, built in America by Americans.’”

To view the full press release, visit https://ibn.fm/X1ET1

About Mullen Automotive Inc.

Mullen is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover, Mullen-GO Commercial Urban Delivery EV, Mullen Commercial Class 1-3 EVs and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and Class 4-6 commercial offerings. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition of Electric Last Mile Solutions’ (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana. For more information about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has closed its previously announced public offering. The offering was comprised of 5,384,615 shares of common stock (or common stock equivalents in lieu thereof) and warrants; the shares were offered at $1.30 per share (or common stock equivalent in lieu thereof) and accompanying warrant. According to the announcement, the warrants also had an exercise price of $1.30 per share, as well as being exercisable immediately upon issuance; the warrants will expire five years after the initial exercise date. The company noted that total gross proceeds for the offering reached an estimated $7 million before the deduction of agent fees and other offering expenses. The company anticipates using the proceeds from the offering to repay an approximately $0.2 million outstanding convertible promissory note and advance development programs as well as for general corporate purposes.

To view the press release, visit https://ibn.fm/51wvl

About PaxMedica Inc.

PaxMedica is a forward-looking, clinical-stage biopharmaceutical firm specializing in cutting-edge, anti-purinergic drug therapies (“APT”) aimed at addressing a range of challenging neurologic disorders, including autism spectrum disorder (“ASD”) and human African trypanosomiasis (“HAT”). The company’s portfolio encompasses critical areas within the neurology field, with a focus on pioneering advancements in both ASD and HAT treatments. PaxMedica is dedicated to the continuous development and evaluation of its pioneering program, PAX-101, an intravenous suramin formulation that lies at the heart of the company’s efforts, particularly focused on innovative ASD and HAT treatment solutions. The company’s ongoing research initiatives not only prioritize the needs of ASD and HAT patients but also extend to exploring potential therapeutic applications for related conditions. For more information about the company, visit www.PaxMedica.com.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

• D-Wave third-quarter revenue grew by 51% year-over-year
• D-Wave’s third quarter bookings increased by 53% year-over-year, representing the company’s sixth consecutive quarter of year-over-year booking growth, while the first three quarters bookings increased by 125% when compared to the year earlier period
• CEO Dr. Alan Baratz recently met with Members of Congress to urge them to support the reauthorization of the National Quantum Initiative and ensure that it was expanded to encompass all quantum computing technologies

D-Wave Quantum (NYSE: QBTS), a leader in commercial quantum computing systems, software, and services, recently announced financial results for its fiscal third quarter, which ended September 30, 2023. D-Wave CEO Dr. Alan Baratz believes this is a pivotal moment in quantum computing, as the company leads the industry’s transformative shift from research and developmental experimentation to true delivery of quantum’s enterprise value and utility. “Our annealing quantum computing solutions are driving real business impact today, and we believe that our third quarter results reflect a growing recognition that D-Wave is leading the enterprise quantum wave,” said Baratz (https://ibn.fm/gUqPU).

Notable third-quarter financial highlights for the company include…

Read More>>

Forward Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this press release include, but are not limited to, statements regarding the potential for D-Wave to bring the power of quantum to artificial intelligence and machine learning to its customers and the potential impact of the National Quantum Initiative legislation. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including whether the initiatives set forth in the NQI are implemented and, if so, the success of such initiatives general economic conditions and other risks; the company’s ability to expand its customer base and the customer adoption of its solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against us; risks related to the performance of the company’s business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of the company’s products; the effects of competition on its business; the risk that D-Wave will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the company may never achieve or sustain profitability; the risk that the company is unable to secure or protect its intellectual property; volatility in the price of the company’s securities; the risk that its securities will not maintain the listing on the NYSE; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to D-Wave on the date hereof. D-Wave undertakes no duty to update this information unless required by law.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced the presentation of updated safety data from its ongoing potentially pivotal study evaluating Berubicin. According to the announcement, the data showed the comparability of the patient demographics in the two arms of the study, and of the safety data for each therapeutic modality in treating recurrent Glioblastoma Multiforme (“GBM”). The data was presented in a poster presentation at the 28th annual Society of NeuroOncology meeting, which was held Nov. 15–19, 2023, in Vancouver, Canada. The poster, which was titled “A randomized, controlled trial of Berubicin vs. Lomustine after first-line therapy for glioblastoma multiforme (GBM): Interim Results,” is now available to view on the company’s website. Berubicin is CNS Pharmaceutical’s novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. The company’s CMO, Sandra Silberman, MD, PhD, presented the poster. “We continue to be encouraged by the preliminary safety data from Berubicin and are committed to moving this program forward,” said CNS Pharmaceuticals chief medical officer Dr. Sandra Silberman in the press release. “The preclinical and phase 1 clinical results give us reason to hope that Berubicin will ultimately be shown to provide a much-needed clinical benefit for GBM patients, and we remain on track to report the results of our interim analysis of efficacy data in December.”

To view the poster, visit https://ibn.fm/y2P9U

To view the full press release, visit https://ibn.fm/Y8enV

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information about the company, please visit www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Renovaro BioSciences (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, was featured in a recent Proactive interview. Mark Dybul, CEO of Renovaro, joined host Steve Darling to talk about the company and its achievements and potential. Specifically, the two talked about the company’s recent signing of a definitive agreement to merge with GEDiCube, a United-Kingdom-based medical artificial intelligence (“AI”) company renowned for its contributions to the early detection and remission of cancer, as well as expedited drug discovery. During the interview, Dybul discussed the plan to rebrand GEDiCube as Renovaro.AI and then have the two entities work together to accelerate diagnosis processes, improve the efficacy of treatments, pioneer new therapies, and broaden the availability of vital technologies for cancer and other diseases.

Dybul also mentioned that although Renovaro is focused on pancreatic cancer research, the company is planning to extend its focus to include other solid tumors that are typically associated with a short life expectancy. Part of that expansion will include making those tumors as part of the first human phase I/IIa studies anticipated to commence by mid-2024. Dybul also talked about the potential of GEDiCube’s AI technology to support the company’s focus of upcoming human trials on those cancers that are most amenable to treatment. In addition, the company expects the technology to supplement the database of crucial markers for early diagnosis and tracking disease progression, consequently furthering the development of novel iterations of Renovaro’s treatment methodologies and the discovery of new therapeutic options.

To view the interview, visit https://ibn.fm/YMdv3

To view the full press release, visit https://ibn.fm/4TKf0

About Renovaro BioSciences Inc.

Renovaro BioSciences has developed advanced cell, gene and immunotherapy platforms designed to renew the body’s natural tumor-fighting capabilities against cancer and infectious diseases. For more information about the company, visit www.RenovaroBio.com.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

Turbo Energy S.A. (NASDAQ: TURB), a leading photovoltaic energy-storage technology company based in Valencia, Spain, is featured in a recent episode of IBN’s The Bell2Bell Podcast. According to the announcement, Turbo Energy general manager Mariano Soria joined host Stuart Smith to discuss the company and its business model, as well as the renewable energy space and the company’s potential looking forward. IBN is a multifaceted communications organization dedicated to connecting public companies to the investment community. Part of its sustained effort to provide specialized content distribution via widespread syndication channels, the Bell2Bell Podcast provides delivers informative updates and exclusive interviews with executives operating in fast-moving industries. “Turbo Energy is part of a group with more than 20 years of experience in photovoltaic energy,” said Turbo Energy general manager Mariano Soria during the interview. “Photovoltaic storage has become more and more popular, and Turbo Energy, wanting to stay at the technological forefront, has been investing in innovation and developing its own software. Now, Turbo Energy no longer talks about just batteries; we talk about advanced photovoltaic energy-management solutions for residential, commercial and industrial clients. The renewable energy sector has been growing very quickly in recent years, and we understand that it will not stop doing so throughout the world. . . . This fact, together with rapid growth in the consumption of electric vehicles, will probably favor the energy transition, but it will also present us with a strong technological challenge relating to the management of electrical energy. This is the challenge we want to address at Turbo Energy. . . . Our energy storage system is prepared to protect homes and businesses against the risk of being left without electricity or having to pay dearly for it. Investing in photovoltaics and storage is investing in security and service to the community, even service to the environment.”

To view the full episode, visit https://ibn.fm/fK4mf

To view the full press release, visit https://ibn.fm/kmVeU

About Turbo Energy S.A.

Turbo Energy is a leading photovoltaic energy-storage technology company based in Valencia, Spain. The company’s focus is on developing innovative solutions that allow end consumers to harness the full potential of solar energy and reduce their electricity costs. With a combination of artificial intelligence and advanced technology, Turbo Energy is paving the way toward a more sustainable and energy-efficient future. For more information, visit the company’s website at www.Turbo-E.com.

NOTE TO INVESTORS: The latest news and updates relating to TURB are available in the company’s newsroom at http://ibn.fm/TURB

About GreenEnergyStocks

GreenEnergyStocks (“GES”) is a specialized communications platform with a focus on companies working to shape the future of the green economy. GreenEnergyStocks is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, GES is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, GES brings its clients unparalleled recognition and brand awareness. GES is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from GreenEnergyStocks, text “Green” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenEnergyStocks.com

Please see full terms of use and disclaimers on the GreenEnergyStocks website applicable to all content provided by GES, wherever published or re-published: https://www.greennrgstocks.com/Disclaimer

GreenEnergyStocks
Los Angeles, CA
www.GreenEnergyStocks.com
310.299.1717 Office
[email protected]

GreenEnergyStocks is powered by IBN

• Genprex was granted orphan drug designation by the FDA earlier this year for development of REQORSA combined with Tecentriq in small cell lung cancer
• Use of REQORSA combined with Tecentriq is the subject of Genprex’s upcoming Acclaim-3 clinical trial
• Genprex took part in two events in October – the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; and Genprex’s own hosted event, a Virtual Key Opinion Leaders on Bringing Gene Therapy to the Fight Against Lung Cancers

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes, was granted orphan drug designation (“ODD”) by the US Food and Drug Administration (“FDA”) for its REQORSA(R) immunogene therapy for the combination of its immunogene therapy REQORSA(R) and Genentech Inc.’s Tecentriq(R) as maintenance therapy in patients with extensive stage small cell lung cancer (“SCLC”) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment earlier this year.

The FDA can grant ODD to a drug or biological product being developed to prevent, diagnose, or treat rare diseases or conditions. The designation is intended to spark innovation among biotech companies developing treatments for the more than 30 million people suffering from…

Read More>>

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to GNPX are available in the company’s newsroom at https://ibn.fm/GNPX

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

• Clene is focused on developing and commercializing novel clean-surfaced nanotechnology (“CSN(R)”) therapeutics
• The company utilizes an electro-crystallization nanotherapeutics platform, which results in nanocrystals that exhibit catalytic activities multiple times higher than numerous other commercially available nanoparticles that the company has comparatively evaluated
• Clene is focusing on central nervous system (“CNS”) disorders like amyotrophic lateral sclerosis (“ALS”), multiple sclerosis (“MS”), and Parkinson’s disease (“PD”)
• Its lead investigational product, CNM-Au8(R), has so far demonstrated a good safety and tolerability profile, with Phase 2 trials suggesting efficacy in ALS patients

Nanotechnology has attracted a great deal of the scientific community’s attention thanks to its ability to deliver medicinally attractive nanoparticles (“NPs”) with promising performances that are directly attributable to such properties as ease of cellular uptake, stability, solubility, synthetic accessibility, and release pattern and cell penetration.

Studies investigating the therapeutic capabilities of metallic NPs such as selenium, silver, and gold, as well as metallic oxides like zinc oxide and aluminum oxide, have documented their potential anti-diabetic, antibacterial, antiviral, and antiparasitic capabilities (https://ibn.fm/OwfF4). Moreover, metallic…

Read More>>

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

Renovaro BioSciences (NASDAQ: RENB), an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy, recently announced a definitive agreement to combine with the advanced AI company GEDiCube International Ltd, rebranding as Renovaro AI. “The company has also announced the addition of three new members to its board of directors – Avram Miller, Leni Boeren and Ruud Hendriks. Leni Boeren brings a 40-year career in the financial sector, with banking roles at Paribas and Rabobank… Ruud Hendriks brings over 35 years of experience in asset management, having held senior roles at some of the most established financial institutions… Avram Miller is an American businessperson, corporate venture capitalist, scientist, and technologist who served as vice president of business development for Intel Corporation and co-founded Intel Capital, a division of Intel Corporation set up to manage corporate venture capital, global investment, mergers and acquisitions,” reads a recent article. “I look forward to supporting the company in unlocking the vast potential of the two companies. Together, we are committed to spearheading advancements in the battle against cancer and other diseases, harnessing cutting-edge AI technology and pioneering biotherapeutics,” Boeren is quoted as saying.

To view the full article, visit https://ibn.fm/P378d

About Renovaro BioSciences Inc.

Renovaro has developed advanced cell, gene and immunotherapy platforms designed to renew the body’s natural tumor-fighting capabilities against cancer and infectious diseases. For more information on Renovaro, visit the company’s website at www.Renovarobio.com.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

• Longeveron recently released topline results from its Phase 2a trial evaluating Lomecel-B(TM) as a potential treatment for mild AD
• The study met its primary safety endpoint across all four study groups and showed positive and statistically significant results in secondary endpoint involving the Composite Alzheimer’s Disease Score (“CADS”) for Lomecel-B(TM) and components of the CADS
• The positive results are expected to form the basis for further development of Lomecel-B(TM) as a potential treatment for mild AD

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions for which there is an unmet medical need, announced on October 5 its topline results from its Phase 2a trial, called the CLEAR MIND trial, investigating Lomecel-B(TM) for the treatment of mild Alzheimer’s disease (“AD”) (https://ibn.fm/b6G9m). The announcement was featured in a recent NetworkNewsAudio (“NNA”) broadcast, which is part of an overall goal to deliver additional visibility, recognition, and brand awareness in the investment community (https://ibn.fm/gSIll).

Lomecel-B(TM) is an allogeneic medicinal signaling cell (“MSC”). MSCs appear to possess anti-inflammatory, pro-vascular, and pro-regenerative…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LGVN are available in the company’s newsroom at http://ibn.fm/LGVN

Forward-Looking Statements

Certain statements in this press release that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “believe,” “expects,” “may,” “looks to,” “will,” “should,” “plan,” “intend,” “on condition,” “target,” “see,” “potential,” “estimates,” “preliminary,” or “anticipates” or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, the anticipated use of proceeds from the offering, as well as statements about the ability of Longeveron’s clinical trials to demonstrate safety and efficacy of the company’s product candidates, and other positive results; the timing and focus of the company’s ongoing and future preclinical studies and clinical trials and the reporting of data from those studies and trials; the size of the market opportunity for the company’s product candidates, including its estimates of the number of patients who suffer from the diseases being targeted; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of the company’s product candidates; the company’s ability to obtain and maintain regulatory approval of its product candidates in the U.S., Japan and other jurisdictions; the company’s plans relating to the further development of its product candidates, including additional disease states or indications it may pursue; the company’s plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and its ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and the company’s ability to attract and retain such personnel; the company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the company’s need to raise additional capital, and the difficulties it may face in obtaining access to capital, and the dilutive impact it may have on its investors; market and other conditions; the company’s financial performance and ability to continue as a going concern, and the period over which it estimates its existing cash and cash equivalents will be sufficient to fund its future operating expenses and capital expenditure requirements. Further information relating to factors that may impact the company’s results and forward-looking statements are disclosed in the company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 14, 2023 and its Quarterly Report on Form 10-Q for the third quarter of 2023 filed with the SEC on November 9, 2023. The forward-looking statements contained in this press release are made as of the date of this press release, and the company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

• SuperCom, a global leading provider of traditional and digital identity solutions, just announced its latest order from the Romanian government to the tune of $3.4 million
• SuperCom will help Romania’s Ministry of Interior to bolster its EM project, based on its PureSecurity Suite, covering domestic violence monitoring, GPS tracking of offenders, as well as home detection monitoring
• Deliveries are set to be met by the end of Q4 2023, and SuperCom’s management is optimistic that the order will boost the company’s overall value proposition and lead to many more orders down the line

SuperCom (NASDAQ: SPCB), a leading global provider of traditional and digital identity solutions offering advanced safety, identification, and security products and solutions to governments, recently announced its continued collaboration with the Romanian government. The latest order from the country’s Ministry of Interior is part of an ongoing $30 million project, bolstering the country’s National Electronic Monitoring (“EM”) Project (https://ibn.fm/VALGi).

The EM program is based on SuperCom’s PureSecurity Suite, covering domestic violence monitoring, GPS tracking of offenders, and home detection monitoring. This end-to-end suite offers a secure real-time software platform. Years of testing and on-ground application have proven its effectiveness, affirming…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

About TechMediaWire

TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer

TechMediaWire
Los Angeles, CA
www.TechMediaWire.com
310.299.1717 Office
[email protected]

TechMediaWire is powered by IBN

• Lexaria, a global innovator in drug delivery platforms, has, since 2014, continuously worked on its patented DehydraTECH(TM) drug delivery technology
• The technology has demonstrated overall effectiveness in enhanced delivery of fat-soluble molecules through the human gastrointestinal system, as affirmed by clinical testing
• This overall effectiveness and push for its development has earned Lexaria 37 granted patents globally, with many patents pending
• The company is constantly enhancing its patent portfolio, since granted patents can support an increase in licensing revenue

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is eyeing growth in license revenue from its intellectual property (“IP”). Since 2014, the company has continuously worked on its flagship technology – the patented DehydraTECH(TM) drug delivery technology – which has demonstrated the improvement of speed of onset, brain absorption, and bioavailability (https://cnw.fm/HZKIV). It is being investigated in association with dementia treatment, nicotine replacement, hypertension, and heart disease treatment, among other applications (https://cnw.fm/y5ECe).

So far, Lexaria has received 37 granted patents globally, with many patents pending. The company is aggressively pushing its patent application process as it recognizes the viable commercial application of its flagship technology. In addition, the company understands that successfully granted patents can lead…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (“CBDW”) is a specialized communications platform with a focus on CBD related news and updates in the cannabidiol (“CBD”) sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled recognition and brand awareness.

CBDW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CBDWire, text “CBDWire” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://www.CBDWire.com/Disclaimer

CBDWire
Denver, CO
www.CBDWire.com
303.498.7722 Office
[email protected]

CBDWire is powered by IBN

• Turbo Energy in September 2023 announced its successful debut on the Nasdaq stock exchange
• The company operates as a subsidiary of Umbrella Solar Investment S.A.
• Turbo Energy’s total revenue for the year ended December 31, 2022, increased by 82% year-over-year to €31,148,676 (approximately $33,321,219)
• In October 2023, the company was awarded a software patent in Spain related to its flagship Sunbox product

Turbo Energy (NASDAQ: TURB) designs, develops and distributes equipment for the generation, management and storage of photovoltaic energy in Spain, Europe and internationally.

Turbo Energy’s products include lithium-ion batteries and inverters. Additionally, the company recently launched its flagship product, the Sunbox, an all-in-one device that integrates most of the equipment required for a residential photovoltaic installation. The Sunbox is powered by AI and features a…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to TURB are available in the company’s newsroom at https://ibn.fm/TURB

About GreenEnergyStocks

GreenEnergyStocks (“GES”) is a specialized communications platform with a focus on companies working to shape the future of the green economy. GreenEnergyStocks is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, GES is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, GES brings its clients unparalleled recognition and brand awareness. GES is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from GreenEnergyStocks, text “Green” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenEnergyStocks.com

Please see full terms of use and disclaimers on the GreenEnergyStocks website applicable to all content provided by GES, wherever published or re-published: https://www.greennrgstocks.com/Disclaimer

GreenEnergyStocks
Los Angeles, CA
www.GreenEnergyStocks.com
310.299.1717 Office
[email protected]

GreenEnergyStocks is powered by IBN

• SenesTech Inc., a visionary leader in fertility control to manage animal pest populations, has developed products that show success in limiting rat populations using unique non-lethal fertility reduction products
• Rodents are often associated with carrying diseases that can affect humans, and SenesTech’s non-lethal population-reducing technology targets this major problem in a uniquely humane, environmentally conscious, yet effective way
• The Arizona-based company has developed two primary products — its liquid ContraPest(R) brand, and the recently introduced Evolve(TM) Soft Bait formulation, soft bait being favored by rodent control professionals
• The company anticipates using their technology to develop similar pest-control products for other species in the near future

Close on the heels of introducing a new product expected to create exponential revenue growth for the company, pest animal control innovator SenesTech (NASDAQ: SNES) reported its Q3 financial status to investors Nov. 9, highlighting the company’s continued progress in a year that has seen a record sequential quarterly increase in its earnings.

An archived recording of the Q3 report can be found on SenesTech’s Investor Relations page, at…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the pricing of its public offering of an aggregate of 5,384,615 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 5,384,615 shares of common stock, at a combined public offering price of $1.30 per share (or common stock equivalent in lieu thereof) and accompanying warrant. According to the announcement, the warrants will be exercisable immediately upon issuance, at an exercise price of $1.30 per share, and will expire five years after the initial exercise date. Subject to the satisfaction of customary conditions, the closing is expected to occur on or about Nov. 22, 2023. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

To view the full press release, visit https://ibn.fm/hw4F2

About PaxMedica Inc.

PaxMedica is a forward-looking clinical-stage biopharmaceutical firm specializing in cutting-edge anti-purinergic drug therapies (“APT”) aimed at addressing a range of challenging neurologic disorders, including autism spectrum disorder (“ASD”) and human African trypanosomiasis (“HAT”). Its portfolio encompasses critical areas within the neurology field, with a focus on pioneering advancements in both ASD and HAT treatments. The company is dedicated to the continuous development and evaluation of its pioneering program, PAX-101-an intravenous suramin formulation that lies at the heart of its efforts, particularly focused on innovative ASD and HAT treatment solutions. PaxMedica’s ongoing research initiatives not only prioritize the needs of ASD and HAT patients but also extend to exploring potential therapeutic applications for related conditions. For more information about the company, visit www.PaxMedica.com.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

Renovaro BioSciences (NASDAQ: RENB), an advanced, preclinical biotechnology company, and GEDi Cube Intl Ltd., an AI medical technology company, previously announced a definitive agreement to combine. The move brings together two innovative platforms in AI and biotherapeutics to offer comprehensive solutions spanning early detection, diagnostic insights and targeted immunotherapies. “According to CEO Dr. Mark Dybul, MD, the AI division intends to launch commercial products for early cancer detection and improved therapy selection in 2024 – rapidly expanding the precision medicine market, which Renovaro is positioned to capture a substantial share of the largely untapped market. The immunotherapy division plans to start Phase 1/2 trials of its lead asset in the second half of 2024, a breakthrough approach Dr. Dybul believes could lead to emergency use authorization as soon as the end of 2027 – following the results of a Phase 2 clinical trial that will transform treatment for cancers with low survival rates, like pancreatic cancer,” reads a recent article. “We believe GEDiCube’s AI technology will enhance and accelerate the development of treatments we are currently pursuing as well as power the discovery of new therapeutic approaches for cancer and other diseases,” Dr. Dybul is quoted as saying.

To view the full article, visit https://ibn.fm/cMKtu

About Renovaro BioSciences Inc.

Renovaro has developed advanced cell, gene and immunotherapy platforms designed to renew the body’s natural tumor-fighting capabilities against cancer and infectious diseases. For more information on Renovaro, visit the company’s website at www.Renovarobio.com.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, is spotlighted in a recent NetworkNewsAudio broadcast. According to the broadcast, the company recently announced that it had met with the U.S. Food and Drug Administration (“FDA”) in a Type-B meeting, designed to discuss the positive results from the company’s PAX-HAT-301 study of suramin in stage one human African sleeping sickness caused by Trypanosoma brucei rhodesiense, a rare and fatal parasitic disease. The broadcast was released by via NetworkNewsAudio (“NNA”), a solution that offer companies additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. “This marks a pivotal moment for PaxMedica, and we are encouraged by the constructive feedback from the FDA in our recent type-B meeting,” said PaxMedica CEO and chair Howard Weisman regarding the meeting. “The guidance received is instrumental as we expedite the final steps toward our NDA submission for PAX-101, expected in the second half of 2024. We are particularly focused on completing the production of commercial lots under CMC regulatory guidelines, anticipating substantial time and cost savings. We are committed to advancing efficiently in the months ahead to bring PAX-101 closer to those in need.”

To view the full broadcast, visit https://ibn.fm/0S6F3

To view the press release, visit https://ibn.fm/dxEhW

About PaxMedica Inc.

PaxMedica is a forward-looking, clinical-stage biopharmaceutical firm specializing in cutting-edge anti-purinergic drug therapies (“APT”) aimed at addressing a range of challenging neurologic disorders, including autism spectrum disorder (“ASD”) and human African trypanosomiasis (“HAT”). The company’s portfolio encompasses critical areas within the neurology field, with a focus on pioneering advancements in both ASD and HAT treatments. PaxMedica is dedicated to the continuous development and evaluation of its pioneering program, PAX-101, an intravenous suramin formulation that lies at the heart of our efforts, particularly focused on innovative ASD and HAT treatment solutions. The company’s ongoing research initiatives not only prioritize the needs of ASD and HAT patients but also extend to exploring potential therapeutic applications for related conditions. For more information about the company, visit www.PaxMedica.com.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company focused on developing innovative therapies for central nervous system disorders, specifically aggressive brain cancers. The company today announced its confidence in sharing the results from an interim analysis on one of its lead treatment candidates, Berubicin, with the public before the end of the year. Berubicin is a chemotherapy drug that interferes with the DNA of cancer cells to inhibit their growth and potentially shrink tumors. Distinct from other anthracyclines, a clinically trusted class of drugs in use for 60 years against dozens of common cancers, and other traditional chemotherapy drugs, CNS Pharmaceuticals reports that Berubicin has the ability to penetrate the blood-brain barrier and directly target cancer cells in the brain, increasing its potential effectiveness.

In October, the company announced that 229 out of 243 expected patients had already been enrolled in its ongoing study evaluating the effectiveness of Berubicin for recurrent glioblastoma (“GBM”), a highly aggressive and incurable form of brain cancer. The global critical and adaptive trial involves multiple centers and is open-label, randomized and controlled, comparing Berubicin to Lomustine – a drug unapproved for this indication but still used as the standard of care – in adult patients with recurrent GBM (WHO Grade IV) after standard first-line therapy has failed. CNS Pharmaceuticals had set a specific goal to analyze the efficacy data after more than half of the patients enrolled in the study reached the primary endpoint. During this analysis, an independent data safety monitoring board (“DSMB”) closely examines the number of deaths in each treatment group to ensure that Berubicin patients show a significant improvement in overall survival compared to those receiving Lomustine. In addition, other important factors are considered, such as how long patients live without the cancer progressing, response rates and safety. The interim analysis will conclude if Berubicin is at least as effective as Lomustine, in which case the DSMB will make a recommendation that the trial continue.

To view the full press release, visit https://ibn.fm/HPKDP

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

• D-Wave and QuantumBasel announced a two-year extension to the strategic agreement between the companies to accelerate quantum and quantum-hybrid application development in Europe
• D-Wave will open a European office on the QuantumBasel campus to establish an onsite presence supporting the companies’ joint efforts to fast-track the region’s commercialization of quantum computing
• D-Wave’s European customers include QuantumBasel, BBVA, Koç Holding, Satispay, Poznan Superconducting and Network Center, and Cineca

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services and the world’s first commercial supplier of quantum computers, and QuantumBasel, Switzerland’s quantum innovation hub, recently announced a two-year extension to the strategic agreement between the companies to accelerate quantum and quantum-hybrid application development in Europe.

As a part of the agreement, D-Wave will open a European office on the QuantumBasel campus to establish an onsite presence supporting the companies’ joint efforts to fast-track the region’s commercialization of quantum computing. D-Wave’s commitment to opening its European office…

Read More>>

Forward-Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this press release include, but are not limited to, statements regarding the opening of D-Wave’s European office, and the potential benefits of D-Wave’s European presence and the continued collaboration between D-Wave and QuantumBasel. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the availability of office space at QuantumBasel, general economic conditions and other risks; the company’s ability to expand its customer base and the customer adoption of its solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against the company; risks related to the performance of the company’s business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of the company’s products; the effects of competition on its business; the risk that the company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that D-Wave may never achieve or sustain profitability; the risk that the company is unable to secure or protect its intellectual property; volatility in the price of the company’s securities; the risk that the company’s securities will not maintain the listing on the NYSE; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. The company undertakes no duty to update this information unless required by law.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, announced that its partner, the Randy Marion Automotive Group (“RMA”), has received its North Carolina license to retail Mullen’s commercial EVs. According to the announcement, this is a required dealer license that allows the auto group to move vehicles to customers. According to RMA officials, the organization is seeing “tremendous interest” in Mullen’s Class 1 and Class 3 vehicles. The new dealer license allows the company to immediately begin delivering Mullen EVs. Beginning Nov. 20, 2023, the company will begin shipping Class 3 vehicles to Adventure Coast Rentals in Tennessee and Georgia, Godotek in Michigan and NRTC Automation Group in Alabama. RMA also anticipates receiving a new shipment of completed vehicles from Mullen. The vehicles in that shipment are all presold and will go to Duke Energy, Merchants Fleet and MGT Leasing. Mullen noted that the Class 1 vehicle production line at its Tunica assembly plant began on Nov. 1, 2023, and the company is now running both Class 1 and Class 3 production lines simultaneously at the facility, with plans to deliver 150 Class 3 and 300 Class 1 vehicles by the end of this year. “It’s exciting to see both Class 1 and Class 3 vehicle production fully operational and our Class 3 heading to customers,” said Mullen Automotive CEO David Michery in the press release. “We fully expect to accomplish our production and delivery goals for 2023.”

To view the full press release, visit https://ibn.fm/QL4RL

About Mullen Automotive Inc.

Mullen Automotive is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover; the Mullen I-GO Commercial Urban Delivery EV; the Mullen commercial class 1–3 EVs; and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and class 4–6 commercial offerings. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition of Electric Last Mile Solutions (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana. To learn more about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, is reporting on its financial results as well as providing a comprehensive business update for the third quarter ended Sept. 30, 2023. Highlights of the report include the successful conclusion of a crucial Type-B meeting with the U.S. Food and Drug Administration designed to gather vital guidance for the NDA submission of PAX-101; the completion of the final PAX-101 phase 3 trials for human African trypanosomiasis (HAT); the strategic acquisition of suramin research assets from Rediscovery Life Sciences (RLS); and the successful completion of a commercial-scale development plan for PAX-101, which shows the company is on track for manufacturing API validation, drug-product validation and registration lots in the first quarter of 2024. The company’s financial report showed a total of $1.2 million in cash reserves with access to the remaining $14.4 million from the company’s committed equity investment agreement, with a total count of common shares issued and outstanding as of the end of the quarter reaching 1,073,815. “The accomplishments in the third quarter of 2023 represent significant progress in our journey towards a 2024 US FDA filing of an NDA for the treatment of HAT with PAX-101 (IV suramin),” said PaxMedica CEO Howard Weisman in the press release. “The favorable results from our retrospective HAT-301 study reinforce the substantial benefits of suramin in treating this life-threatening infection. With these milestones, PaxMedica is well-positioned to expand our research initiatives, including the exploration of PAX-101 for addressing the core symptoms of autism spectrum disorder.”

To view the full press release, visit https://ibn.fm/B2qxm

About PaxMedica Inc.

PaxMedica is a forward-looking, clinical-stage biopharmaceutical firm specializing in cutting-edge anti-purinergic drug therapies (“APT”) aimed at addressing a range of challenging neurologic disorders. The company’s comprehensive portfolio encompasses a spectrum of conditions, including neurodevelopmental disorders such as autism spectrum disorder (ASD), as well as other critical areas within the neurology field. PaxMedica is dedicated to the continuous development and evaluation of its pioneering program, PAX-101, an intravenous suramin formulation that lies at the heart of the company’s efforts, particularly focused on innovative ASD treatment solutions. The company’s ongoing research initiatives not only prioritize the needs of ASD patients but also extend to exploring potential therapeutic applications for related conditions. For more information about the company, visit www.PaxMedica.com.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

• Fr8Tech CEO recently wrote a letter to shareholders summarizing the company’s financial milestones and operational successes
• CEO Javier Selgas discussed the company’s robust revenue growth in Q2 2023 as well as the 93% year-over-year increase in its gross margins during the first half of the year
• The company’s commitment to innovation has led to the launch of an LTL offering and the establishment of an AI department
• Fr8Tech has successfully expanded into new markets, completed a number of strategic integrations with third-party solutions, and grown its customer base

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a technology company whose lead product is Fr8App, an industry-leading freight-matching platform powered by artificial intelligence (“AI”) and machine learning, is making substantial strides in the realization of its objectives. In a letter to shareholders, CEO Javier Selgas summarized the company’s recent financial milestones and operational successes that underscore its commitment to achieving continued growth (https://ibn.fm/21HPi).

This growth is reflected in Fr8Tech’s financial results for the second quarter of 2023, which ended June 30, 2023. The company, Selgas wrote, “achieved robust revenue growth, marking a substantial 29% increase compared to the preceding quarter.” Selgas observed the growth attests to Fr8Tech’s…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT

Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

About TechMediaWire

TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer

TechMediaWire
Los Angeles, CA
www.TechMediaWire.com
310.299.1717 Office
[email protected]

TechMediaWire is powered by IBN

NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, was featured in an interview with Proactive, where its CEO Charlie Fernandez joined host Steve Darling to provide an update on the company’s latest financial results. NextPlat has made impressive strides in consolidating its global e-commerce and Progressive Care health care operations, leading to significant growth. During the interview, Fernandez highlighted the company’s strong financial performance in the third quarter, reporting consolidated revenues of $15.3 million. This represents a remarkable >481% increase compared to the third quarter of the previous year. In addition, the company’s gross margins saw substantial improvement, reaching 30% for the quarter ending on Sept. 30, 2023, up from the previously reported 26%. These financial results demonstrate NextPlat’s effective consolidation efforts and its ability to drive revenue and improve profitability. The company is well positioned to build on its success and deliver value to its stakeholders as it continues to expand its operations and explore new opportunities in the e-commerce and health care sectors.

To view the full article, visit https://ibn.fm/d0wZ6

About NextPlat Corp.

NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and markets including technology and healthcare. Through acquisitions, joint ventures and collaborations, the company intends to assist businesses in selling their goods online, domestically and internationally, allowing customers and partners to optimize their e-commerce presence and revenue. NextPlat currently operates an e-commerce communications division offering voice, data, tracking, and IoT products and services worldwide and pharmacy and healthcare data management services in the United States.

NOTE TO INVESTORS: The latest news and updates relating to NXPL are available in the company’s newsroom at https://ibn.fm/NXPL

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is steadily advancing its patented DehydraTECH(TM) technology for a growing range of applications including oral nicotine, hypertension, antivirals, human hormone therapy, diabetes and more. Through previous clinical trials, DehydraTECH-processed CBD has shown its ability to lower blood pressure in patients over multiple weeks. “That we were able to lower blood pressure in our patient population over multiple weeks using DehydraTECH-CBD is an exceptional discovery, given that previous studies by others using other oral CBD formulations have failed to evidence this sustained benefit,” a recent article quotes Lexaria CEO Chris Bunka as saying. “This success has been replicated in other studies, most notably diabetes. In Lexaria’s pre-clinical diabetes study, DIAB-A22-1, conducted in obese diabetic-conditioned animals, DehydraTECH-CBD yielded successful results showing positive impacts on blood glucose levels, overall body weight, locomotor activity, in addition to triglyceride and blood urea nitrogen levels… Lexaria’s DehydraTECH has also proven its superiority and advantage over traditional oral delivery methods in the nicotine replacement market… ‘Within just five short years of R&D and product development, Lexaria has been able to develop an oral nicotine product that meets or exceeds the performance of the world’s leading existing brands,’ noted Mr. Bunka.”

To view the full article, visit https://cnw.fm/PMphs

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 37 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is powered by IBN

SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal pest populations, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 12 pre-split shares. According to the announcement, the reverse stock split will become effective at 4:01 p.m., Eastern Time, on Nov. 16, 2023. The company’s common stock will continue to trade on the Nasdaq Capital Market under the symbol SNES and will begin trading on a split-adjusted basis when the market opens on Nov. 17, 2023. At a special meeting held on Aug. 18, 2023, the company’s stockholders granted the company’s board of directors the discretion to effect a reverse stock split of the company’s common stock through an amendment to its Amended and Restated Certificate of Incorporation, as amended, at a ratio of not less than 1-for-2 and not more than 1-for-12, with such ratio to be determined by the board.

To view the full press release, visit https://ibn.fm/qA1Rj

About SenesTech Inc.

SenesTech is committed to improving the health of the world by humanely managing animal pest populations through fertility control. The company is an expert in fertility control to manage animal pest populations. It invented ContraPest(R), the only U.S. EPA-registered contraceptive for male and female rats, and Evolve(TM), an EPA-designated minimum risk contraceptive currently offered for rats. ContraPest and Evolve fit seamlessly into all integrated pest management programs, significantly improving the overall goal of effective pest management. SenesTech strives for clean cities, efficient businesses and happy households – with a product designed to be humane, effective and sustainable. For more information about the company, visit www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is reporting on its financial results for third quarter, the period ended Sept. 30, 2023; the company also noted upcoming milestones. Notable financial numbers from the report include net loss for Q3 totaled approximately $4.5 million compared to an estimated $3.4 million for the comparable period in 2022; R&D expenses came in at $3.4 million for the third quarter compared to approximately $2.2 million for the comparable period in 2022; and general and administrative expense reached approximately $1.1 million. CNS reported cash of approximately $0.9 million with an additional $2.6 million in a warrant inducement transaction and placements on the ATM facility.

Operationally, the company noted that enrollment numbers rose to 239 participants in the ongoing potentially pivotal study of Berubicin for treatment of GBM, with expected full enrollment by next month; topline data from preplanned interim analysis from the Berubicin study is also expected next month. “Over the course of 2023, we have demonstrated solid execution and rapid progression of enrollment in our ongoing potentially pivotal study of Berubicin,” said CNS Pharmaceuticals CEO John Climaco in the press release. “We are preparing for the most significant milestones for patients, the company and our stockholders in just a few short weeks. . . . With topline data from our interim analysis expected in the coming weeks, we are poised to determine whether or not the independent Data Safety Monitoring Board recommends continuing the study. We are hopeful that by the end of this study, Berubicin will ultimately demonstrate life-saving value as a second-line treatment for patients with recurrent glioblastoma. We look forward to an exciting remainder of the year and building value for all stakeholders in the near and long-term.”

To view the full press release, visit https://ibn.fm/7hSI1

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. For more information about the company, please visit www.CNSPharma.com

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, allowing for the creation of rich data for artificial intelligence (“AI”), is reporting its financial and operational results for the third quarter ended Sept. 30, 2023. Highlights of the report include the publication of a foundational study demonstrating the ability of HeartBeam’s VECG technology platform to detect the presence of coronary artery occlusions in the “Journal of American College Cardiology”; several new management and board of director appointments; and significant progress made toward key milestones for the company’s VECG device. That progress includes receiving and responding to questions from the U.S. Food and Drug Administration (“FDA”) regarding the initial AIMIGo 510(k) submission; holding a presubmission meeting with the FDA on the second AIMIGo 510(k) submission; and receiving a third patent for the 12-Lead Extended Wear Patch designed for detecting heart attacks and complex cardiac arrythmias.

Key financial numbers reported by the company include R&D expenses for Q3 2023 totaled $1.6 million, compared to $1.6 million for the Q3 2022; general and administrative expenses for the quarter were $2.1 million compared to $2 million for the third quarter of 2022; and net loss for the third quarter of 2023 was $3.5 million, compared to a net loss of $3.6 million for the same period in 2022. “During the third quarter of 2023 we significantly enhanced the HeartBeam team, continued to make steady progress toward upcoming clinical and regulatory milestones, and validated the potential of our VECG technology platform,” said HeartBeam founder and CEO Branislav Vajdic, PhD, in the press release. “We ended the third quarter of 2023 with approximately $19.2 million in cash and cash equivalents, and believe we are in a strong position as we carefully manage spending to extend our runway. Earlier in the year we closed a $26.5 million in common stock-only financing, which we believe will fund our operations into early 2025. We look forward to providing updates on our progress in the months ahead.”

To view the full press release, visit https://ibn.fm/FY2eX

About HeartBeam Inc.

HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform intended for patient use at home. By applying a suite of proprietary algorithms to simplify vector electrocardiography (“VECG”), the HeartBeam platform enables patients and their clinicians to assess cardiac symptoms quickly and easily so care can be expedited if required. HeartBeam AIMIGo is the first and only credit card-sized, 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system to facilitate remote heart-attack detection. By collecting 3D signals of the heart’s electrical activity, HeartBeam AIMIGo has the potential to provide unparalleled data for the development of AI algorithms. HeartBeam AIMIGo has not yet been cleared by the U.S. Food and Drug Administration (FDA) for marketing in the United States or other geographies. For more information, visit www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Turbo Energy (NASDAQ: TURB), a leader in photovoltaic energy storage, was featured in an interview with Proactive London after the Spain-based company completed its Nasdaq listing in the U.S. Turbo Energy’s General Manager Mariano Soria joined Thomas Warner from Proactive to provide an overview of the business, describing it as being “at the forefront of technology for storing photovoltaic energy” and explaining how the company is utilizing artificial intelligence to help improve its offering. He shares how the company uses AI to help its customers save money by analyzing energy usage patterns and cross-referencing the data with weather and energy-price forecasts to maximize efficient deployment of stored energy. Soria further explains that the learning done by the company over the last ten years has gone into its primary product, called the SunBox — a plug-and-play solution that can be installed in a user’s home very quickly and with minimal training. He also discusses plans for the future, saying that he is expecting explosive growth given that Turbo Energy has “probably the most advanced system for cost-savings in residential photovoltaics.”

To view the full interview, visit https://ibn.fm/C6GDc

About Turbo Energy S.A.

Turbo Energy is a leading photovoltaic energy storage technology company based in Valencia, Spain. The company’s focus is on developing innovative solutions that allow end consumers to harness the full potential of solar energy and reduce their electricity costs. With a combination of artificial intelligence and advanced technology, Turbo Energy is paving the way towards a more sustainable and energy-efficient future. For more information, visit the company’s website at www.Turbo-e.com.

NOTE TO INVESTORS: The latest news and updates relating to TURB are available in the company’s newsroom at https://ibn.fm/TURB

About GreenEnergyStocks

GreenEnergyStocks (“GES”) is a specialized communications platform with a focus on companies working to shape the future of the green economy. GreenEnergyStocks is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, GES is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, GES brings its clients unparalleled recognition and brand awareness. GES is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from GreenEnergyStocks, text “Green” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenEnergyStocks.com

Please see full terms of use and disclaimers on the GreenEnergyStocks website applicable to all content provided by GES, wherever published or re-published: https://www.greennrgstocks.com/Disclaimer

GreenEnergyStocks
Los Angeles, CA
www.GreenEnergyStocks.com
310.299.1717 Office
[email protected]

GreenEnergyStocks is powered by IBN

• SuperCom’s wholly owned subsidiary, Leaders in Community Alternatives, Inc. (“LCA”), recently won a new contract to supply alcohol monitoring technologies and services in California
• The contract is valued at up to $3 million over the initial 3-year term, based on anticipated usage estimates
• Since 2003, LCA has provided continuous transdermal alcohol monitoring (“CAM”) programs for thousands of California drivers found driving under the influence (“DUI”)
• The alcohol monitoring programs use tamper-proof tags worn around the ankle to measure the amount of alcohol in an offender’s body by taking a sample of their sweat every 30 minutes
• SuperCom’s reputation for providing reliable and high-quality electronic monitoring services was pivotal in securing the new contract, President and CEO Ordan Trabelsi said

SuperCom (NASDAQ: SPCB), a leading global provider of traditional and digital identity solutions, provides advanced safety, identification, connectivity, and security products and solutions to governments as well as public and private organizations around the world. The Tel Aviv, Israel-headquartered company wholly owns several active subsidiaries, including, among others, Leaders in Community Alternatives, Inc. (“LCA”).

Acquired in January 2016, LCA is a California-based, private criminal justice organization running electronic monitoring programs and providing community-based services under contracts with various government agencies in the United States. According to SuperCom, LCA has significantly bolstered the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

About TechMediaWire

TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer

TechMediaWire
Los Angeles, CA
www.TechMediaWire.com
310.299.1717 Office
[email protected]

TechMediaWire is powered by IBN

D-Wave (NYSE: QBTS) is a leader in quantum computing systems, software and services and the world’s first commercial supplier of quantum computers. The company has announced important research results that demonstrate successful Quantum Error Mitigation (“QEM”) in its Advantage2(TM) annealing quantum computing experimental prototype. According to the announcement, the techniques reduce errors in quantum simulations, producing results consistent with the quantum system maintaining its quantum state (“coherence”) for an order of magnitude longer time than an unmitigated system. D-Wave expects to leverage these techniques to drive performance advancements in the forthcoming Advantage2 system and future processors.

“Errors represent the most significant obstacle in all forms of quantum computation,” said Mohammad Amin, fellow, quantum algorithms and systems, who led the research at D-Wave. “This work demonstrates the successful mitigation of such errors in quantum annealing, producing measurement results as if the qubits were nearly one order of magnitude more coherent. This enables computation in regimes that were previously inaccessible, such as quantum simulations of exotic magnetic materials, an important milestone on the road to demonstrating quantum supremacy on D-Wave processors.”

To view the full article, visit https://ibn.fm/wO1iU

About D-Wave Quantum Inc.

D-Wave is a leader in the development and delivery of quantum computing systems, software and services, and is the world’s first commercial supplier of quantum computers — and the only company building both annealing quantum computers and gate-model quantum computers. The company’s mission is to unlock the power of quantum computing today to benefit business and society. D-Wave does this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection and financial modeling. D-Wave’s technology has been used by some of the world’s most advanced organizations including Volkswagen, Mastercard, Deloitte, Davidson Technologies, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, Forschungszentrum Jülich, University of Southern California, and Los Alamos National Laboratory. For more information, visit the company’s website at www.dwavequantum.com.

Forward-Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this press release include, but are not limited to, statements regarding the expected impact of the techniques for QEM on D-Wave’s forthcoming Advantage2 system and future processors. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the continued success of the techniques used in the research; general economic conditions and other risks; our ability to expand our customer base and the customer adoption of our solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against us; risks related to the performance of our business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of our products; the effects of competition on our business; the risk that we will need to raise additional capital to execute our business plan, which may not be available on acceptable terms or at all; the risk that we may never achieve or sustain profitability; the risk that we are unable to secure or protect our intellectual property; volatility in the price of our securities; the risk that our securities will not maintain the listing on the NYSE; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today released financial results for the first quarter of the fiscal year 2024, which ended Sept. 30, 2023. “We are pleased with the continued advancements across our pharmaceutical programs and commercial operations. We are particularly excited with the recent candidate selection and official launch of our INM-901 preclinical program targeting the treatment of Alzheimer’s disease, representing a unique and innovative treatment approach compared to current options available to patients. Our commercial subsidiary, BayMedica, continues to make steady progress as a B2B supplier of rare cannabinoids to the Health and Wellness sector as our trailing 12-month sales trend continues to show steady growth,” said InMed CEO Eric A. Adams. “Furthermore, the successful completion of a recent financing further strengthens our balance sheet and provides additional financial stability in a particularly challenging capital markets environment. These additional funds extend our cash runway into calendar 3Q 2024.”

To view the full press release, visit https://ibn.fm/EVRgY

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. The company also has significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. For more information, visit www.InMedPharma.com and www.BayMedica.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

About TinyGems

TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, CA
www.TinyGems.com
310.299.1717 Office
[email protected]

TinyGems is powered by IBN

Progressive Care (OTCQB: RXMD), a personalized health care services and technology provider, today announced financial results for its third quarter ended Sept. 30, 2023. Among the highlights, the company reported record third quarter revenues of $12 .4 million, a 22% increase in comparison to the prior year period, driven primarily by strong growth at its PharmcoRx pharmacies. “We are thrilled with our third quarter results and the significant continued growth of Progressive Care, highlighted by strength in our pharmacy and 340B contract businesses. Our performance is a direct result of our commitment to improving outcomes for patients through medical adherence,” said Charles M. Fernandez, chairman and CEO of Progressive Care. “During a time when the broader pharmacy sector and the entire health care industry increasingly faces mounting pressures to improve care while reducing costs, our team continues to capitalize on the many growth opportunities in front of us including expanding our services for our existing patients and partnering with organizations that can provide us with the potential to reach large numbers of new customers.”

In addition, NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, which consolidated the operations of its e-commerce business with the results of its health care operations, Progressive Care, today announced its financial results for the three months ended Sept. 30, 2023. “The third quarter of 2023 marks an inflection point for NextPlat as we report the consolidation of our global e-commerce and Progressive Care health care operations. As a unified business, our teams are focused on maximizing the value of each of its operations through the launch of new online storefronts for customers including OPKO Health into China’s multibillion-dollar marketplace on Alibaba’s Tmall Global, and the further expansion of Progressive Care’s services for both patients and providers,” said Charles M. Fernandez, executive chairman and CEO of NextPlat. “The intersection of technology, global e-commerce and health care creates tremendous opportunities for NextPlat. Our continued growth is supported by strong, debt-free balance sheets with sufficient cash to invest both internally and in acquisitions that can quickly add scale to our platform. It is through these investments that we intend to create greater synergies in our business as we seek to unlock valuable new benefits for our customers, partners, patients, and shareholders.”

To view the full press releases, visit https://ibn.fm/FLxYa and https://ibn.fm/VOCtq

About Progressive Care Inc.

Progressive Care, through its subsidiaries, is a Florida health services organization and provider of third-party administration (“TPA”), data management, COVID-19-related diagnostics and vaccinations, 340B contracted pharmacy services, prescription pharmaceuticals, compounded medications, provider of tele-pharmacy services, the sale of anti-retroviral medications, medication therapy management (“MTM”), the supply of prescription medications to long-term care facilities, and health practice risk management.

NOTE TO INVESTORS: The latest news and updates relating to RXMD are available in the company’s newsroom at https://ibn.fm/RXMD

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

SuperCom Ltd. (NASDAQ: SPCB), a global provider of secured solutions for the e-Government, IoT and cybersecurity sectors, today announced financial and operating results for the three and nine months ended Sept. 30, 2023. “We are excited to announce exceptional operational performance for Q3 2023, which is reflected in our financial results. A 5-year record net profit, remarkable 550% growth in EBITDA and 74% growth in gross profit margins are clear indicators of the successful execution of our growth strategy. The significant increase in the company’s profit margins is driven by the forward momentum we’ve maintained across our projects, where margins typically enhance as projects mature. This trend is an indicator of further potential margin expansion when project timelines align,” said Ordan Trabelsi, president and CEO of SuperCom. “As we look to the future, SuperCom is uniquely positioned to capitalize on the increasing global demand for secured electronic monitoring solutions. We are strategically investing in the continuous improvement of our offerings and extending our reach into new markets, which is already yielding promising results in the U.S. and other regions. Our focus remains on driving innovation, enhancing operational efficiencies, and delivering exceptional value to our customers and stakeholders. We are confident that our strategic decisions will further propel us towards achieving our long-term objectives and securing SuperCom’s position as a leader in the industry.”

To view the full press release, visit https://ibn.fm/CTMKr

About SuperCom

Since 1988, SuperCom has been a global provider of traditional and digital identity solutions, providing advanced safety, identification and security solutions to governments and organizations, both private and public, throughout the world. Through its proprietary e-Government platforms and innovative solutions for traditional and biometrics enrollment, personalization, issuance and border control services, SuperCom has inspired governments and national agencies to design and issue secure multi-ID documents and robust digital identity solutions to its citizens and visitors. SuperCom offers a unique all-in-one field-proven RFID & mobile technology and product suite, accompanied by advanced complementary services for various industries including healthcare and homecare, security and safety, community public safety, law enforcement, electronic monitoring, livestock monitoring, and building and access automation. For more information about the company, visit www.Supercom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Longeveron (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, was featured in the latest episode of the Bell2Bell Podcast, a part of IBN’s sustained effort to provide specialized content distribution via widespread syndication channels. Longeveron’s CEO Wa’el Hashad joined the program to introduce the company and its business model. “Longeveron is a cell therapy-based biotech company. It was established in 2014 as a spin-off from a technology that was developed at the University of Miami School of Medicine by a renowned scientist and cardiologist, Dr. Josh Hare,” Hashad said. “Josh has been working since he graduated medical school… on trying to help patients regenerate their heart muscles after heart attacks. He continued to use stem cells – specifically mesenchymal stem cells, or medicinal signaling cells – to try to develop medicines that may help patients have a better outcome after heart attacks and so on… He moved to aging-related diseases, and, as a cardiologist, he had a passion for a very rare condition called hypoplastic left heart syndrome, a congenital heart disease that affects about 1,000 babies born every year in this country. He was so passionate about HLHS that he worked with other experts to initiate HLHS trials which have led to some promising outcomes thus far, and we continue to march forward. So, that’s how the company was founded. It is dedicated to advancing medicines in areas of longevity and rare diseases.”

To view the full press release, visit https://ibn.fm/9WDH7

About Longeveron Inc.

Longeveron is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The company’s lead investigational product is Lomecel-B(TM) an allogeneic medicinal signaling cell (“MSC”) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B(TM) has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently advancing Lomecel-B(TM) through clinical trials in three indications: hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty. Additional information about the company is available at www.Longeveron.com.

NOTE TO INVESTORS: The latest news and updates relating to LGVN are available in the company’s newsroom at http://ibn.fm/LGVN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software and services as well as the world’s first commercial supplier of quantum computers, has announced support for new Congressional legislation. According to the announcement, the company applauds National Quantum Initiative (“NQI”) legislation that includes all quantum computing systems and focuses on near-term application development. In addition, D-Wave CEO Dr. Alan Baratz met with members of Congress earlier this year, urging their support to reauthorize the NQI and ensure that the legislation is expanded to encompass all quantum-computing technologies, including annealing, gate model and quantum-hybrid. The new legislation is designed to expand the NQI and pushes for additional commercialization efforts while also supporting industry engagement within U.S. quantum programs, a dedicated near-term quantum application development program, and an overarching inclusion of all quantum computing systems and quantum-hybrid technologies.

The announcement called the NQI “watershed legislation” that serves as the public sector roadmap for establishing the path forward for the U.S. quantum industry. The legislation is designed to assist in determining how the federal government can use quantum technology to provide solutions to a variety of challenges impacting individuals, communities and the economy. The previous act expired on Sept. 30, 2023.

“We commend the House Science Committee for introducing NQI legislation that is inclusive of all quantum technologies, including quantum annealing and quantum-hybrid technologies,” said D-Wave Quantum CEO Dr. Alan Baratz in the press release. “Reauthorizing and expanding the NQI will strengthen U.S. quantum programs and move the U.S. closer to global leaders like Japan, the U.K., Australia and Germany, which are already heavily investing in near and long-term quantum technology and supporting commercialization efforts. Congress must act quickly to ensure that U.S. programs remain competitive to global counterparts.”

To view the full press release, visit https://ibn.fm/OVD6a

About D-Wave Quantum Inc.

D-Wave is a leader in the development and delivery of quantum computing systems, software and services, and is the world’s first commercial supplier of quantum computers — and the only company building both annealing quantum computers and gate-model quantum computers. The company’s mission is to unlock the power of quantum computing today to benefit business and society. D-Wave does this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection and financial modeling. D-Wave’s technology has been used by some of the world’s most advanced organizations, including Volkswagen, Mastercard, Deloitte, Davidson Technologies, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, Forschungszentrum Jülich, University of Southern California, and Los Alamos National Laboratory. For more information about the company, please visit www.dwavequantum.com.

Forward-Looking Statements

Certain statements in this newsbreak are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this newsbreak include, but are not limited to, statements regarding the potential impacts of reauthorizing and expanding the NQI. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including whether the initiatives set forth in the NQI are implemented and, if so, the success of such initiatives; general economic conditions and other risks; our ability to expand our customer base and the customer adoption of our solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against us; risks related to the performance of our business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of our products; the effects of competition on our business; the risk that we will need to raise additional capital to execute our business plan, which may not be available on acceptable terms or at all; the risk that we may never achieve or sustain profitability; the risk that we are unable to secure or protect our intellectual property; volatility in the price of our securities; the risk that our securities will not maintain the listing on the NYSE; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this newsbreak in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

• Lexaria, a global innovator in drug delivery platforms, is exploring the impact of its patented DehydraTECH(TM) technology on the oral performance of GLP-1 drugs for potential diabetes and weight loss treatment
• The company hopes to make these drugs more effective with reduced side effects, and even more accessible to people living with diabetes
• The move is aimed to help the company partner with the behemoths in an industry projected to bring in between $150 billion and $200 billion a year

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is evaluating the impact of its patented DehydraTECH(TM) technology on the oral performance of GLP-1 drugs for the treatment of diabetes and weight loss. DehydraTECH has demonstrated, in many instances, significant improvement in how active pharmaceutical ingredients (“APIs”) enter the bloodstream with its powerful bioavailability enhancing capabilities. The move could help Lexaria carve out an important market share for an industry that is projected to bring in between $150 billion and $200 billion a year (https://cnw.fm/1KdgW). Given the positive results the company has achieved so far in its diabetes and hypertension clinical studies, Lexaria is optimistic that its foray into GLP-1 drugs will yield positive results and open up its technology to new and more lucrative global markets.

According to the U.S. Centers for Disease Control (“CDC”), obesity prevalence in the U.S. stood at 41.9% in 2017. In addition, the World Health Organization (“WHO”) noted that over 1.9 billion people worldwide are overweight as of 2016, underscoring the spike in diabetes diagnoses. This growing population of people living with this condition has seen the diabetes drug market grow over the years. It is projected to hit $82.93 billion in value by 2027, up from $63.1 billion in 2021 (https://cnw.fm/aUbV9). Given this prevalence, along with the pain and unpleasantness of injections that many people living with diabetes have to deal with…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is powered by IBN

SuperCom (NASDAQ: SPCB), a global provider of secured solutions for the e-government, Internet of Things (“IoT”) and cybersecurity sectors, has scheduled a call and webcast for tomorrow to discuss its financial results for Q3 2023, the period ended Sept. 30, 2023. The call is slated to begin at 10 a.m. ET. According to the announcement, financial results for the company will be released prior to the call. The call, which will include a Q&A session, will be hosted by SuperCom management. Those wanting to access the call can dial 888-506-0062 (toll free in the United States), 1-809-423-853 (toll free in Israel) or 973-528-0011 (international). Callers are encouraged to call in 10 minutes prior to the start time to allow time for an operator to connect the call.

To view the webcast, visit https://ibn.fm/8Kvbe

To view the full press release, visit https://ibn.fm/i63dJ

About SuperCom Ltd.

SuperCom has been a global provider of traditional and digital identity solutions since 1988, providing advanced safety, identification, and security solutions to governments and organizations, both private and public, worldwide. Through its proprietary e-government platforms and innovative solutions for traditional and biometrics enrollment, personalization, issuance and border control services, SuperCom has inspired governments and national agencies to design and issue secure multi-ID documents and robust digital identity solutions to its citizens and visitors. SuperCom offers a unique all-in-one, field-proven Radio Frequency Identification (“RFID”) and mobile technology and product suite, accompanied by advanced complementary services for various industries including healthcare and homecare, security and safety, community public safety, law enforcement, electronic monitoring, livestock monitoring, and building and access automation. For additional information about this company, please visit www.SuperCom.com

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

About TechMediaWire

TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer

TechMediaWire
Los Angeles, CA
www.TechMediaWire.com
310.299.1717 Office
[email protected]

TechMediaWire is powered by IBN

• PaxMedica is developing PAX-101, which utilizes the company’s proprietary source of suramin sodium, for the treatment of ASD (Autism Spectrum Disorder)
• There is no FDA-approved treatment for the core symptoms of autism, even though the rates of autism spectrum disorder have jumped significantly from 2000 to 2020
• ASD is characterized by deficits in social communication, restricted and repetitive patterns of behavior, and significant impairment in functioning, three core aspects of the disease that PaxMedica aims to address
• The company announced positive topline results from a Phase 2 study evaluating PAX-101 as a potential treatment for ASD and hopes to replicate these results in a larger trial, for which PaxMedica is preparing

In the U.S., the rates of autism spectrum disorder (“ASD”), a diverse group of early-onset and lifelong neurodevelopmental conditions, have more than quadrupled from 2000 to 2020, according to data published by the Centers for Disease Control and Prevention (“CDC”) (https://ibn.fm/fRYhj). Researchers attribute the increase to advances in diagnostic capabilities as well as greater understanding and awareness of ASD (https://ibn.fm/v6gtI). PaxMedica (NASDAQ: PXMD) is a clinical-stage biopharmaceutical company intent on developing novel anti-purinergic therapies (“APTs”) for the treatment of ASD and other serious conditions.

Estimates from the CDC’s Autism and Development Disabilities Monitoring (“ADDM”) Network, which pools data from multiple sites across the United States, showed that about 1 in 36 children had been identified with ASD in 2020, up from 1 in 150 in 2000. Correspondingly, the combined prevalence per…

Read More>>

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software and services, is reporting its numbers for the third quarter of 2023. Highlights of the report included revenue of $2.6 million for the quarter, an increase of 50% sequentially from Q2 and an increase of 51% on a year over year basis. Commercial revenue increased by 62% year over year and constituted 70% of total revenue over the last four quarters, up from 50% over the prior four quarters. Q3 bookings totaled $2.9 million, up 53% on a year-to-year basis with Q3 representing the company’s sixth consecutive quarter of year over year growth in quarterly bookings. The company also reported a $53.3 million cash balance, the highest in the company’s history.

The report also noted recent commercial and business highlights, including the signing of a number of new and expanded existing customer engagements and working with commercial customers on a variety of new quantum and quantum-hybrid applications that include customer rewards optimization, radar scheduling for national security, HVAC system design optimization, 6G satellite network optimization and much more. Additionally, the report noted the company’s initiation of exploration of its quantum technology’s integration with new machine learning areas to bring the power of quantum to artificial intelligence and machine learning for its customers.

“We believe that this is a pivotal moment in quantum computing, as D-Wave leads the industry’s transformative shift from research and developmental experimentation to true delivery of quantum’s enterprise value and utility,” said D-Wave Quantum CEO Dr. Alan Baratz in the press release. “Our annealing quantum computing solutions are driving real business impact today, and we believe that our third-quarter results reflect a growing recognition that D-Wave is leading the enterprise quantum wave. Once again, we experienced quarter-over-quarter and year-over-year growth in the number of customer bookings, commercial revenue, and the size of commercial deals. We’re also seeing customers moving from development to deployment of applications, as they are seeing first-hand the business impact and near-term advantage that can be achieved using D-Wave’s annealing quantum computing solutions. That growing commercial success, coupled with our ongoing world-class product development and scientific advancements, reflect, in our opinion, impressive progress across all facets of our business.”

To view the full press release, visit https://ibn.fm/wf9tj

About D-Wave Quantum Inc.

D-Wave is a leader in the development and delivery of quantum computing systems, software and services, and is the world’s first commercial supplier of quantum computers. The company’s mission is to unlock the power of quantum computing today to benefit business and society. D-Wave does this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection and financial modeling. D-Wave’s technology has been used by some of the world’s most advanced organizations, including Volkswagen, Mastercard, Deloitte, Davidson Technologies, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, Forschungszentrum Jülich, University of Southern California, and Los Alamos National Laboratory. For more information about the company, please visit www.dwavequantum.com.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced a new high-energy facility in Fullerton, California, which expands the company’s overall U.S. footprint, including EV battery development and production capabilities. According to the announcement, the new Southern California facility is dedicated to producing next-generation American-made EV battery packs, a critical component to the company’s commitment to zero emissions. Mullen’s high-energy pilot facility in Monrovia, California, will be consolidated with the recently purchased Romeo Power assets at the company’s new high-energy and high-volume battery pack production facility in Fullerton, California. “We are one step closer to fulfilling our commitment to providing the next-generation of battery technology to our lineup of EV vehicles, providing a clean and safe alternative to current lithium-ion batteries,” said David Michery, CEO and chairman of Mullen Automotive.

To view the full press release, visit https://ibn.fm/uc72j

About Mullen Automotive Inc.

Mullen is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover, Mullen-GO Commercial Urban Delivery EV, Mullen Commercial Class 1-3 EVs and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and Class 4-6 commercial offerings. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition of Electric Last Mile Solutions’ (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana. For more information about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-Related Frailty, is reporting on data from a long-term study. According to the announcement, extended long-term, follow-up data from Longeveron’s  ELPIS I trial of Lomecel-B(TM) for patients with hypoplastic left heart syndrome (“HLHS”) is being presented as a poster at the annual Scientific Sessions of the American Heart Association (AHA); those sessions are being held this week, Nov. ­11­-13, 2023, in Philadelphia. The poster for the sessions is titled “Long-Term Transplant-Free Survival Is Improved in Hypoplastic Left Heart Syndrome with Cell-Based Therapy.” The poster shows that study data reported 100% of the 10 patients participating in the ELPIS I trial survived and remained heart transplant-free for up to five years of age after receiving Lomecel-B during their stage 2 surgery. Extended follow-up data on all patients enrolled in the study now reflects monitoring for up to five years following treatment with Lomecel-B, with additional follow-up ongoing.

By comparison, historical results from other studies report that children with HLHS experience approximately 20% mortality by five years of age. “Long-term follow-up data from our ELPIS I trial demonstrate the continued survival of the participants, and reinforce potential survival benefit of Lomecel-B for patients with HLHS,” said Longeveron cofounder, chief science officer, and board chair Joshua M. Hare, MD, in the press release. “These data represent an additional up to two years of follow-up data, which point to the potential of Lomecel-B in this indication and provide support for our ongoing ELPIS 2 study, which has exceeded its 50% enrollment threshold. We anticipate completing enrollment in this trial in 2024. There is an unmet need to improve the transplant-free survival for patients with HLHS, and we hope Lomecel-B can significantly improve the treatment landscape for this patient population.”

To view the full press release, visit https://ibn.fm/sItIL

About Longeveron Inc. 

Longeveron is a clinical-stage, biotechnology company developing regenerative medicines to address unmet medical needs. The company’s lead investigational product is Lomecel-B(TM), an allogeneic medicinal signaling cell (“MSC”) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action encompassing provascular, proregenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently advancing Lomecel-B through clinical trials in three indications: hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty. To learn more about the company, visit www.Longeveron.com.

NOTE TO INVESTORS: The latest news and updates relating to LGVN are available in the company’s newsroom at https://ibn.fm/LGVN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

• Arizona-based SenesTech Inc. provides a unique approach to rodent pest control by formulating a contraceptive that works as birth control in both male and female rats
• A major milestone has been reached by the company as it recently began taking orders for its new Evolve(TM) Soft Bait formulation, which joins SenesTech’s liquid ContraPest(R) brand as a population-control solution that avoids some of the problems associated with lethal rodenticides
• The Evolve(TM) Soft Bait product is targeting the vast professional pest control market that prefers a non-liquid product, as well as providing a consumer-friendly option that may be marketed through big box retailers and e-commerce providers
• SenesTech’s operation has been growing rapidly this year, and company officers stated last month that its “pro forma cash balance” is $4 million with no long-term debt

With the advent of cooler weather in the Northern Hemisphere, rodents become more noticeable in homes and buildings as they seek warmer refuge. Pest control giant Orkin estimates mice and other rodents invade around 21 million homes across the United States each fall, according to its annual report on the “50 rattiest cities” (https://ibn.fm/0X9O6).

Rodent control innovator SenesTech (NASDAQ: SNES) is using its own unique approach to the science of reducing rat populations to help clients and pest control companies enjoy the holiday season without such unwanted guests. They have developed a means of birth control for the rodents that keeps their…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, has announced business updates and financial results for the third quarter ended Sept. 30, 2023. Among the highlights, the company reported $3.8 million in total revenue for the third quarter of 2023, an increase of 112% compared to the prior year comparable period and 38% sequentially. The company attributed revenue growth to record shipment volumes. “For the second consecutive quarter, we set new company records for shipment volumes for the automotive end market,” said Jun Pei, Cepton’s co-founder and CEO. “Our continued dedication to executing our milestones and increasing adoption in targeted smart application markets demonstrates our technology leadership in lidar.”

To view the full press release, visit https://ibn.fm/ZMePK

About Cepton Inc.

Cepton is a Silicon Valley innovator of lidar-based solutions for automotive (“ADAS/AV”), smart cities, smart spaces and smart industrial applications. With its patented lidar technology, Cepton aims to take lidar mainstream and achieve a balanced approach to performance, cost and reliability, while enabling scalable and intelligent 3D perception solutions across industries. Cepton has been awarded a significant ADAS lidar series production award with Koito on the General Motors business. Cepton is also engaged with all top 10 global OEMs. Founded in 2016 and led by industry veterans with decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high-performance, high-quality lidar solutions. Cepton is headquartered in San Jose, California, and has a center of excellence facility in Troy, Michigan, to provide local support to automotive customers in the Metro Detroit area. Cepton also has a presence in Germany, Canada, Japan, India and China to serve a fast-growing global customer base. For more information, visit the company’s website at www.Cepton.com.

NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

About TinyGems

TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, CA
www.TinyGems.com
310.299.1717 Office
[email protected]

TinyGems is powered by IBN

• Clene, a company targeting the treatment of neurodegenerative diseases that severely impact people’s lives, is currently focusing on amyotrophic lateral sclerosis (“ALS”) alongside other neurodegenerative diseases
• The company’s wholly owned subsidiary, Clene Nanomedicine, and two collaborators, Columbia University and Synapticure, are the recipients of a four-year grant totaling $45.1 million
• The grant will support an Expanded Access Protocol (“EAP”) study for Clene’s investigational product, CNM-Au8(R)
• CNM-Au8 is an orally administered gold nanocrystal suspension that is thought to improve mitochondrial health and protect neuronal function to treat neurodegenerative diseases, including ALS
• The EAP study will give patients who did not initially meet the criteria to enroll in a clinical trial an opportunity to try CNM-Au8, which, besides being well tolerated, has improved the survival of ALS patients

In late December of 2021, President Biden signed into law H.R. 3537, the Accelerated Access to Critical Therapies for ALS Act (“Act for ALS”) (https://ibn.fm/oQbSk). The Act for ALS (amyotrophic lateral sclerosis), now public law, directs the Department of Health and Human Services through the Secretary to, among others, “award grants to participating entities for the purposes of scientific research utilizing data from expanded access to investigational drugs for individuals who are not otherwise eligible for clinical trials for the prevention, diagnosis, mitigation, treatment, or cure of ALS” (https://ibn.fm/A2Tuu).

During the financial year 2023, the National Institutes of Health (“NIH”) made strides to implement the Act for ALS, extending its commitment to advancing research on ALS, which currently has no cure. Through its division, the National Institute of Neurological Disorders and Stroke (“NINDS”), the…

Read More>>

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

• The agreement with GEDiCube rebrands the company as a wholly-owned subsidiary under the name Renovaro.AI
• The combined company brings together two innovative platforms in AI and biotherapeutics to offer comprehensive solutions spanning early detection, diagnostic insights, and targeted immunotherapies, for cancer and other diseases
• The AI division intends to launch commercial products for early cancer detection and improved therapy selection in 2024 – rapidly expanding the largely untapped precision medicine market

In September, Renovaro Biosciences (NASDAQ: RENB), an advanced, preclinical biotechnology company focused on cell, gene, and immunotherapy, and GEDiCube Intl Ltd., an AI medical technology company, announced a definitive agreement for combination. Under the stock-for-stock agreement, GEDiCube will become a wholly-owned subsidiary of Renovaro. The company’s CEO, Dr. Mark Dybul, MD, recently sent a letter to Renovaro shareholders to provide an update on the union – sharing the vision of the combination and expressing appreciation for their ongoing support and investment (https://ibn.fm/yFhPk).

“We believe GEDiCube’s AI technology will enhance and accelerate the development of treatments we are currently pursuing as well as power the discovery of new therapeutic approaches for cancer and other diseases,” press releases from the combination announcement quote Dr. Dybul as saying…

Read More>>

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, today announced the expansion of its scientific advisory board (“SAB”) to include several leading cardiologists. New members include Charles L. Brown III, MD, CEO of the Piedmont Healthcare Physician Enterprise, Tony Das, MD, a nationally recognized board-certified interventional cardiology specialist, leader and educator in the field of cardiovascular diseases, Robert Harrington, MD, dean of Weill Cornell Medicine and provost for medical affairs of Cornell University, Campbell Rogers, MD, EVP and chief medical officer at HeartFlow Inc., and Niraj Varma, MD, Ph.D., professor of medicine and consultant electrophysiologist at the Cleveland Clinic. “We are honored and pleased to have such a distinguished group of physicians joining our scientific advisory board,” said Branislav Vajdic, Ph.D., CEO and founder of HeartBeam. “HeartBeam will benefit tremendously from the input of these leaders in interventional cardiology, electrophysiology, clinical research, and new technologies. We look forward to working closely with all the SAB members as we advance our product development, clinical and commercial efforts.”

To view the full press release, visit https://ibn.fm/4BKxk

About HeartBeam Inc.

HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform intended for patient use at home. By applying a suite of proprietary algorithms to simplify vector electrocardiography (“VECG”), the HeartBeam platform enables patients and their clinicians to assess their cardiac symptoms quickly and easily, so care can be expedited, if required. HeartBeam AIMIGo(TM) is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote evaluation of cardiac symptoms. By collecting 3D signals of the heart’s electrical activity, HeartBeam AIMIGo has the potential to provide unparalleled data for the development of AI algorithms. HeartBeam AIMIGo has not yet been cleared by the U.S. Food and Drug Administration (“FDA”) for marketing in the USA or other geographies. For more information, visit www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

• Freight Technologies announced securing a Request for Quotation from a leading global pharmaceutical giant that awards the company 33 lanes of transport pharmaceutical goods from the United States to Canada and Mexico
• The Request for Quotation extends over seven months, and Fr8App will provide uninterrupted, end-to-end logistics solutions, including secure transport, tracking, and reporting for each load
• The company’s dedicated team of professionals will oversee this vital operation to guarantee the smooth and efficient delivery of the pharmaceutical company’s critical products

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a technology company developing solutions to optimize and automate the supply chain process through its custom-developed, industry-leading freight-matching platform powered by AI and machine learning, recently announced securing a Request for Quotation (RFQ) from a leading global pharmaceutical giant. The pharmaceutical conglomerate is known for its commitment to global health and life-changing innovations and has chosen Fr8App as its trusted partner for crucial logistical operations (https://ibn.fm/vyOgV).

Under the terms of the RFQ, Fr8App has been awarded 33 lanes of transport pharmaceutical goods from the United States to Canada and Mexico. The project involves moving one to three loads daily per lane, ensuring timely and secure delivery of vital pharmaceutical products to their…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT

Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Renovaro BioSciences (NASDAQ: RENB), a preclinical biotechnology company involved in the development of enhanced gene, cell and immunotherapy platforms that modulate immune responses against cancers and infectious disease, and GEDi Cube International Ltd., an AI medical technology company, recently entered a definitive agreement to combine in a stock-for-stock acquisition. “The combined company will feature two main divisions: the AI division and the immunotherapy division, according to an Oct. 2 message to shareholders from Renovaro CEO Mark Dybul, M.D. With a mission to transform medicine, the two divisions will leverage the strengths of each other yet maintain flexible independent operations. Bringing together two innovative platforms in biotherapeutics and AI, the combined company intends to create comprehensive solutions for early cancer detection, diagnostic insights and effective targeted immunotherapies,” a recent article reads. “According to Dr. Dybul, GEDi Cube and Renovaro Biosciences came together through a shared desire to turbo-charge innovation and efficacy in precision medicine. The decision to join forces resulted from a carefully considered strategy to combine strengths and synergize work to improve patient outcomes by detecting diseases sooner and matching treatments more precisely based on the individual’s genetic profile.”

To view the full article, visit https://ibn.fm/bPiqr

About Renovaro BioSciences Inc.

Renovaro has developed advanced cell, gene and immunotherapy platforms designed to renew the body’s natural tumor-fighting capabilities against cancer and infectious diseases. For more information on Renovaro, visit the company’s website at www.Renovarobio.com.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, is in the spotlight during a recent episode of The Bell2Bell podcast. During the podcast, PaxMedica chief medical officer David Hough and host Stuart Smith discuss key company achievements, including the company’s recent meeting with the U.S. Food and Drug Administration (“FDA”). Highlights mentioned during the podcast include the discussion with the FDA of data gathered from the company’s PAX-HAT 301 study and other comprehensive nonclinical programs. Hough explained that the study provided positive evidence regarding the company’s treatment for African Sleeping Sickness treatment; he also noted that the FDA acknowledged PaxMedica’s comprehensive nonclinical program, including safety pharmacology and toxicology studies. Hough discussed waivers granted for the studies, affirmed data relevance to the patient population and stated that the anticipated 2024 NDA submission underscores PaxMedica’s commitment to neglected tropical disease treatments. The Bell2Bell podcast is produced by IBN, a leading communications organization focused on linking public companies to the investment community.

To listen to the full podcast, visit https://ibn.fm/lA5ZR

To view the full press release, visit https://ibn.fm/tLmYE

About PaxMedica Inc.

PaxMedica is a forward-looking, clinical-stage biopharmaceutical firm specializing in cutting-edge anti-purinergic drug therapies (“APT”) aimed at addressing a range of challenging neurologic disorders, including autism spectrum disorder (“ASD”) and Human African Trypanosomiasis (“HAT”). The company’s portfolio encompasses critical areas within the neurology field, with a focus on pioneering advancements in both ASD and HAT treatments. PaxMedica is dedicated to the continuous development and evaluation of its pioneering program, PAX-101, an intravenous suramin formulation that lies at the heart of the company’s efforts, particularly focused on innovative ASD and HAT treatment solutions. The company’s ongoing research initiatives not only prioritize the needs of ASD and HAT patients but also extend to exploring potential therapeutic applications for related conditions. For more information about the company, visit www.PaxMedica.com.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

• Lexaria, a global innovator in drug delivery platforms, recently announced plans to launch new human and animal studies examining whether its patented DehydraTECH(TM) technology can make GLP-1 drugs better
• Lexaria has previously demonstrated DehydraTECH’s overall potential in its DIAB-A22-1 animal study, which yielded weight loss, and improved triglyceride and cholesterol levels among diabetic-conditioned animals
• The company plans to replicate the results from this study while also exploring ways to improve the overall bioavailability of GLP-1 drugs for diabetes treatment and weight loss
• Lexaria management is optimistic that it will build on previous studies, replicate previous positive results, and improve the overall efficacy of GLP-1 drugs

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced plans to launch new human and animal studies that seek to examine its patented DehydraTECH(TM) technology’s potential on GLP-1 drugs for the treatment of diabetes and weight loss. This announcement follows the recent study results published on “New England Journal of Medicine,” which showed that 49 to 52 pounds weight loss was a common outcome across the 2,539 adult study participants (https://cnw.fm/bP9IJ).

DehydraTECH has demonstrated, in many instances, significant improvement in how active pharmaceutical ingredients (“APIs”) enter the bloodstream with its strong bioavailability enhancing capabilities. Its unique and revolutionary approach has seen Lexaria granted 37 patents for the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (“CBDW”) is a specialized communications platform with a focus on CBD related news and updates in the cannabidiol (“CBD”) sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled recognition and brand awareness.

CBDW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CBDWire, text “CBDWire” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://www.CBDWire.com/Disclaimer

CBDWire
Denver, CO
www.CBDWire.com
303.498.7722 Office
[email protected]

CBDWire is powered by IBN

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, is expanding its lidar technology presence at the Tampa International Airport (“TPA”). Cepton has partnered with The Indoor Lab, which deploys groundbreaking lidar-based artificial intelligence (“AI”) analytics at the airport. According to the announcement, the partnership is pioneering a first-of-its-kind, lidar-based AI analytics at TPA, which is designed to elevate safety and efficiency 24/7 in both indoor and outdoor environments. The two companies are working to break new ground with products and services that enable a safer, more productive environment from the moment a passenger gets dropped off at the airport to going through security, including boarding the plane and finally taking off. Cepton’s lidar uses eye-safe, invisible light to scan an area without relying on external lighting sources, improving almost every aspect of airport operations, including staffing optimization, cleanliness maintenance, concession-line management, TSA wait-time management and terminal safety. “The Indoor Lab is at the forefront of lidar technology adoption in airport settings,” said Cepton senior vice president of product and commercial operations Brunno Moretti in the press release. “Since 2019, Cepton and the Indoor Lab have been working closely to make air travel safer and more enjoyable for worldwide passengers. We are thrilled to expand the implementation of our lidar technology to cover both indoor and outdoor applications at Tampa International Airport. We believe lidar as a privacy-compliant sensor technology will transform the future of smart spaces.”

To view the full press release, visit https://ibn.fm/eA3Ex

About Cepton Inc.

Cepton is a Silicon Valley innovator of lidar-based solutions for automotive (“ADAS/AV”), smart cities, smart spaces and smart industrial applications. With its patented lidar technology, Cepton aims to take lidar mainstream and achieve a balanced approach to performance, cost and reliability, while enabling scalable and intelligent 3D-perception solutions across industries. Cepton has been awarded a significant ADAS lidar series production award with Koito on the General Motors business. Cepton is also engaged with all top 10 global OEMs. Founded in 2016 and led by industry veterans with decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high-performance, high-quality lidar solutions. Cepton is headquartered in San Jose, California, and has a center of excellence facility in Troy, Michigan, to provide local support to automotive customers in the metro Detroit area. Cepton also has a presence in Germany, Canada, Japan, India and China to serve a fast-growing global customer base. For more information about this company, please visit www.Cepton.com.

NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, is reporting that its phase 2 study research exploring the potential of low-dose suramin intravenous infusions as an autism spectrum disorder (“ASD”) treatment has been published. According to the announcement, the findings from the study were published in the “Annals of General Psychiatry.” The company noted that the research had been led by PaxMedica CMO Dr. David Hough, who worked with a team of renowned ASD specialists. The research was based on a comprehensive, 14-week randomized, double-blind, placebo-controlled study with 52 participants diagnosed with moderate to severe ASD; the participants were boys aged 4 to 15 years of age. The main focus of the study was to evaluate the efficacy and safety of suramin intravenous infusions, with the 10 mg/kg suramin arm demonstrating promising results in the improvement of core symptoms. According to the company, the study revealed statistically significant improvements in the Clinical Global Impressions-Improvement (“CGI-I”) scale among the 10 mg/kg arm compared to the placebo group. “We are highly encouraged by the findings of our study, which provide significant insights into the potential of suramin as a safe and effective treatment for the core symptoms of ASD,” said PaxMedica chief medical officer Dr. David Hough in the press release.

To view the full research article, visit https://ibn.fm/tHy16

To view the full press release, visit https://ibn.fm/IgVAw

About PaxMedica Inc.

PaxMedica is a forward-looking, clinical-stage biopharmaceutical firm specializing in cutting-edge anti-purinergic drug therapies (“APT”) aimed at addressing a range of challenging neurologic disorders, including ASD and Human African Trypanosomiasis (“HAT”). The company’s portfolio encompasses critical areas within the neurology field, with a focus on pioneering advancements in both ASD and HAT treatments. PaxMedica is dedicated to the continuous development and evaluation of its pioneering program, PAX-101, an intravenous suramin formulation that lies at the heart of the company’s efforts, particularly focused on innovative ASD and HAT treatment solutions. The company’s ongoing research initiatives not only prioritize the needs of ASD and HAT patients but also extend to exploring potential therapeutic applications for related conditions. For more information about the company, visit www.PaxMedica.com.

NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Turbo Energy (NASDAQ: TURB), a leader in photovoltaic energy storage, today announced a strategic alliance with French multinational retailer Leroy Merlin to include Turbo’s residential photovoltaic product, Sunbox, in Leroy Merlin’s range of products available in Spain. According to the announcement, the collaboration represents a significant milestone for Turbo Energy and is expected to solidify its position as a pioneer in the field of solar energy in Spain. Turbo Energy’s flagship product, Sunbox, is an innovative all-in-one A.I. solution that integrates all necessary electronics to harness solar energy and provide clean, sustainable and free electricity to homes and businesses. Leroy Merlin, which had a revenue in Spain of €3.3 billion in 2022 and is widely known for its emphasis on environmentally friendly and energy conserving solutions, is an international leader in the world of DIY and construction, serving 500 million customers across 20 countries. “We believe this collaboration with Leroy Merlin will further drive the adoption of photovoltaic energy in Spain and contribute to the global effort to combat climate change,” said Turbo Energy’s General Manager Mariano Soria. “The collaboration is also likely to add meaningful incremental revenue for Turbo Energy in 2024.”

To view the full press release, visit https://ibn.fm/knufI

About Turbo Energy S.A.

Turbo Energy is a leading photovoltaic energy storage technology company based in Valencia, Spain. The company’s focus is on developing innovative solutions that allow end consumers to harness the full potential of solar energy and reduce their electricity costs. With a combination of artificial intelligence and advanced technology, Turbo Energy is paving the way towards a more sustainable and energy-efficient future. For more information, visit the company’s website at www.Turbo-e.com.

About GreenEnergyStocks

GreenEnergyStocks (“GES”) is a specialized communications platform with a focus on companies working to shape the future of the green economy. GreenEnergyStocks is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, GES is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, GES brings its clients unparalleled recognition and brand awareness. GES is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from GreenEnergyStocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenEnergyStocks.com

Please see full terms of use and disclaimers on the GreenEnergyStocks website applicable to all content provided by GES, wherever published or re-published: https://www.greennrgstocks.com/Disclaimer

GreenEnergyStocks
Los Angeles, CA
www.GreenEnergyStocks.com
310.299.1717 Office
[email protected]

GreenEnergyStocks is powered by IBN

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”) is a technology company with a custom-developed Fr8App, an industry-leading freight-matching platform powered by AI and machine-learning offering a real-time portal for B2B cross-border shipping and domestic shipping within the USMCA region. The company today released an open letter from its CEO Javier Selgas addressing concerns regarding recent fluctuations in stock values. “In recent times, we’ve received inquiries about the downward trajectory of our stock… As the CEO of Fr8Tech, I hold your concerns in the highest regard. My paramount duty is to steer our company toward the realization of our objectives, and as I will outline shortly, we are making substantial strides in that direction,” Selgas states in the letter, sharing several recent highlights that underscore the company’s commitment to growth. “In closing, please know that Fr8Tech remains steadfast in its pursuit of innovation, growth and investment in our company’s people and technologies, particularly AI, throughout our platform and its supporting systems. We appreciate your continued support and trust in our vision. We plan to file our six-month financials later this fall and will provide a broad-based update at that time. Together, we will overcome the challenges we face and emerge stronger than ever.”

To view the full press release, visit https://ibn.fm/vQ6gS

About Freight Technologies Inc.

Freight Technologies (“Fr8Tech”) is a technology company developing solutions to optimize and automate the supply chain process. Its wholly owned subsidiary, Freight App Inc. (“Fr8App”), is a B2B cross-border shipping marketplace in the USMCA region powered by AI and machine learning. Focused on making shipping transparent and efficient, Fr8App provides carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road (“OTR”) shipping. Fr8App uses its proprietary technology platform to connect carriers and shippers and significantly improve matching and operation efficiency via innovative technologies such as live pricing and real-time tracking, digital freight marketplace, broker, transportation management, fleet management, and committed capacity solutions. The company is headquartered in Houston, Texas. For more information, please visit Fr8Technologies.com.

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT         

Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

About TechMediaWire

TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer

TechMediaWire
Los Angeles, CA
www.TechMediaWire.com
310.299.1717 Office
[email protected]

TechMediaWire is powered by IBN

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products primarily for the treatment of autoimmune and infectious diseases, has been named the recipient of a grant from the Israel Innovation Authority (“IIA”). According to the announcement, the IIA, which is publicly funded and part of Israel’s Ministry of Economy, approved a nondilutive grant covering 66% of the costs of an ILS 3,536,939 project aimed at ramping up Scinai’s new CDMO business unit; the approximate value of the grant is $900,000. The announcement noted that the grant is not subject to repayment or tied to royalty payments of any kind. The company noted that the award was given after intense due diligence by the IIA, which recognized Scinai’s capabilities to fill an underserved need in Israel’s pharmaceutical R&D ecosystem; the IIA also felt that Scinai’s state-of-the-art GMP biologics manufacturing facility and adjacent R&D and QC laboratories, along with its experienced personnel, are in an ideal position to provide key research and development as well as manufacturing services.

The new business unit will be marketed under the brand Scinai Bioservices and will offer manufacturing process development for protein-based drugs, including host cell transfection/transformation; upstream and downstream process development and scale-up; analytical method development; and cGMP manufacturing for clinical trial supplies, including automatic aseptic filling. “I thank the IIA for its support of Scinai’s plans and their concrete belief in the potential of our business to generate value for stakeholders,” said Scinai Immunotherapeutics CEO Amir Reichman in the press release. “This meaningful nondilutive grant, which is not subject to repayment, will not only advance our CDMO business unit but also provide much-needed relief to our financial position, thereby also indirectly helping our R&D business unit’s drive towards developing our innovative NanoAb-based drug pipeline and clearing the path towards developing Scinai into a company that provides significant benefits to the local and global biopharma and biotech industries, as well as to patients and investors.”

To view the full press release, visit https://ibn.fm/MHJAY

About Scinai Immunotherapeutics Ltd. 

Scinai Immunotherapeutics is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products primarily for the treatment of autoimmune and infectious diseases. With a state-of-the-art facility for biopharmaceutical product development and manufacturing along with highly experienced pharmaceutical industry leadership, Scinai offers end-to-end boutique CDMO services in parallel to developing its own pipeline of diversified and commercially viable products beginning with an innovative nanosized VHH antibody, or NanoAb, pipeline targeting diseases with large unmet medical needs. For more information, visit the company’s website at www.Scinai.com.

NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., today released its third quarter 2023 financial results and provided recent operating highlights for its ALS clinical program. Among the highlights, the company reported statistically significant improved survival benefit of 19.3 months and significantly delayed clinical worsening in patients treated with CNM-Au8(R) in the RESCUE ALS open-label extension trial. “We are pleased to be approaching a meaningful regulatory discussion with the U.S. Food and Drug Administration (‘FDA’) later in the fourth quarter to elucidate key next steps in our ALS regulatory submission of CNM-Au8,” said Rob Etherington, president and CEO of Clene. “We are hopeful that the consistent survival, delayed time to clinical worsening and strong safety profile with CNM-Au8 treatment from two phase 2 independent trials is sufficiently compelling for FDA to consider an accelerated path forward. The unmet need remains high for treatments to improve and extend life for patients living with this highly debilitating and rapidly progressive condition.”

To view the full press release, visit https://ibn.fm/h2nuN

About Clene Inc.

Clene (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8(R) is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8(R) is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products primarily for the treatment of autoimmune and infectious diseases, has received a letter from the NASDAQ Stock Market. Dated Nov. 1, 2023, the letter is regarding SCNI’s noncompliance with the market’s requirement to maintain a minimum bid price of $1 per share. According to the report, Scinai has an initial period of 180 calendar days to regain compliance; that period ends on April 29, 2024. The company will be notified if compliance has been achieved any time during that period. Scinai will closely monitor the closing bid price of its American Depository Shares (“ADSs”) and may consider implementing available options to regain compliance with the minimum bid price requirement. In addition, the company noted that, as disclosed on Oct. 31, 2023, its primary creditor, the European Investment Bank, is considering favorably adjusting the terms of its financial facility contract with the company, specifically by extending the facility’s maturity. “As a result of the potential extension, the company expects a positive impact on Scinai’s shareholders’ equity, which could enable the company to restore compliance with NASDAQ listing rules regarding minimum shareholders’ equity, subject to the discretion of NASDAQ,” stated the announcement. “The NASDAQ letters are only notifications of deficiency and have no immediate effect on the listing or trading of the company’s American Depository Shares.”

To view the full press release, visit https://ibn.fm/bXakc

About Scinai Immunotherapeutics Ltd. 

Scinai Immunotherapeutics is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products primarily for the treatment of autoimmune and infectious diseases. With a state-of-the-art facility for biopharmaceutical product development and manufacturing along with highly experienced pharmaceutical industry leadership, Scinai offers end-to-end boutique CDMO services in parallel to developing its own pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized VHH antibody, or NanoAb, pipeline targeting diseases with large unmet medical needs. For more information, visit the company’s website at www.Scinai.com.

NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

• D-Wave’s new open-source demonstration highlights how its Advantage(TM) quantum computing system can be used to tackle challenges in wireless channel decoding, a growing worldwide problem given the dramatic global growth in wireless connections
• Demonstration shows quantum computing’s ability to tackle challenges of this magnitude relative to classical computation
• Quantum and quantum-hybrid technologies offer value in helping network providers solve a variety of telco-related optimization problems

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software and services, and the world’s first commercial supplier of quantum computers, recently announced the launch of a new open-source demonstration that highlights how its Advantage(TM) annealing quantum computing system can be used to tackle wireless channel decoding problems. The demo, available through the company’s Leap(TM) real-time quantum cloud service, identifies solutions for increasing transmission capacity for wireless and cellular networks using coordinated multipoint decoding.

As the number of mobile connections worldwide approaches 12 billion, the wireless industry requires new solutions to ensure high-quality service levels while reducing operational costs and power requirements. This newly launched demonstration shows how D-Wave’s…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward Looking Statements:

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this press release include, but are not limited to, statements regarding the potential of D-Wave’s technology to improve transmission performance and reduce transmission errors and to out-perform classical computational methods with respect to challenges facing the telecom industry. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including whether the demonstration is successfully translated into production use-cases; general economic conditions and other risks; the company’s ability to expand its customer base and the customer adoption of the company’s solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against the company; risks related to the performance of the company’s business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of the company’s products; the effects of competition on the company’s business; the risk that the company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the company may never achieve or sustain profitability; the risk that the company is unable to secure or protect its intellectual property; volatility in the price of the company’s securities; the risk that the company’s securities will not maintain the listing on the NYSE; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. D-Wave undertakes no duty to update this information unless required by law.

About TechMediaWire

TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer

TechMediaWire
Los Angeles, CA
www.TechMediaWire.com
310.299.1717 Office
[email protected]

TechMediaWire is powered by IBN